<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Cancer-related fatigue: Treatment</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Cancer-related fatigue: Treatment</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Cancer-related fatigue: Treatment</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Carmen P Escalante, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul J Hesketh, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Patricia A Ganz, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sadhna R Vora, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 03, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Fatigue is a common problem in cancer patients, both among those undergoing active cancer treatment and in cancer survivors who have completed treatment. The most important factors contributing to cancer-related fatigue (CRF) are progressive tumor growth, treatment with cytotoxic chemotherapy, biologic response modifiers, molecularly targeted therapy (particularly the small molecular tyrosine kinase inhibitors and therapeutic monoclonal antibodies targeting the vascular endothelial growth factor [VEGF] and epidermal growth factor receptor [EGFR]) or radiation therapy (RT), anemia, pain, emotional distress, sleep disturbance, and poor nutrition. CRF is particularly prevalent with multimodality or dose-intense treatment protocols, and in patients with metastatic disease. (See  <a class="medical medical_review" href="/d/html/2802.html" rel="external">"Cancer-related fatigue: Prevalence, screening, and clinical assessment"</a>.)</p><p>CRF profoundly affects quality of life of both patients and their caregivers, including physical, psychosocial, and economic/occupational aspects [<a href="#rid1">1-7</a>]. Fatigue is routinely identified by patients as one of the most distressing symptoms associated with cancer and its treatment, yet historically it has been consistently underreported and overlooked as a potentially remediable cause of treatment-related morbidity [<a href="#rid8">8</a>]. In contemporary oncologic treatment, however, screening for and treatment of CRF has become a major focus of supportive care. Guidelines from expert groups, including the American Society of Clinical Oncology and National Comprehensive Cancer Network, recommend screening for CRF at the initial visit, after completion of primary therapy, as clinically indicated (and at least annually) during the period of cancer survivorship, at the time that advanced disease is diagnosed, and at all chemotherapy visits [<a href="#rid9">9-11</a>]. Patients who have completed primary treatment and are undergoing posttreatment surveillance should continue to be monitored because fatigue may persist beyond the time of active treatment. (See  <a class="medical medical_review" href="/d/html/2802.html" rel="external">"Cancer-related fatigue: Prevalence, screening, and clinical assessment", section on 'Screening'</a> and  <a class="medical medical_review" href="/d/html/16613.html" rel="external">"Overview of cancer survivorship care for primary care and oncology providers", section on 'Monitoring for late or long-term effects of cancer and its treatment'</a>.)</p><p>Here we will review the management of CRF in patients receiving active cancer treatment and in cancer survivors who have completed treatment. The prevalence of fatigue in patients with cancer, screening and assessment for fatigue in this population, and an overview of fatigue in palliative care patients are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/2802.html" rel="external">"Cancer-related fatigue: Prevalence, screening, and clinical assessment"</a> and  <a class="medical medical_review" href="/d/html/14239.html" rel="external">"Overview of fatigue in palliative care"</a>.)</p><p class="headingAnchor" id="H953061916"><span class="h1">GENERAL APPROACH</span><span class="headingEndMark"> — </span>Some basic principles apply to patients with fatigue during active cancer therapy and cancer survivors who have persistent fatigue after the completion of therapy:</p><p class="bulletIndent1"><span class="glyph">●</span>All patients undergoing active cancer treatment, as well as cancer survivors and their caregivers, should be offered specific information about fatigue during and following treatment (eg, information about the difference between normal and cancer-related fatigue [CRF], persistence of fatigue beyond treatment, and causes and contributory factors).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>All patients with malignant disease should be screened for CRF during active cancer treatment, and as clinically indicated (and at least annually) during follow-up survivor care. The benefits of closely following patient-reported symptoms during treatment was shown in the PROTECT randomized trial, in which routine screening for fatigue and other symptoms using weekly electronic symptom monitoring for at least one year during treatment for metastatic cancer and subsequent intervention that is triggered by severe or worsening symptoms substantially improved patient-reported outcomes as compared with usual care [<a href="#rid12">12</a>]. In an analysis of individual symptom trajectories, significant mean differences in favor of the patient reported outcomes group were observed for fatigue at all time points up to 12 months, and at multiple time points for insomnia. (See  <a class="medical medical_review" href="/d/html/2802.html" rel="external">"Cancer-related fatigue: Prevalence, screening, and clinical assessment"</a>.)</p><p></p><p class="bulletIndent1">For patients with new or worsening CRF, further diagnostic evaluation may be warranted for those with moderate to severe fatigue. (See  <a class="medical medical_review" href="/d/html/2802.html" rel="external">"Cancer-related fatigue: Prevalence, screening, and clinical assessment", section on 'Clinical assessment'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Potentially treatable causes of fatigue should be sought for and treated  (<a class="graphic graphic_table graphicRef98133" href="/d/graphic/98133.html" rel="external">table 1</a>). These include comorbidities (eg, anemia, electrolyte abnormalities, alcohol/substance abuse, endocrine dysfunction [eg, hypothyroidism, hypogonadism, adrenal insufficiency], cardiac, pulmonary, or renal dysfunction), medications, emotional distress, sleep disturbance, pain, nutritional issues (changes in weight/caloric intake), and deconditioning/loss of muscle mass. The clinical team must decide whether referral to an appropriately trained professional (eg, cardiologist, endocrinologist, mental health professional, internist) is needed [<a href="#rid10">10</a>]. (See <a class="local">'Control of contributory factors'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Symptoms that may contribute to fatigue should be managed appropriately (eg, pain, dyspnea, nausea, sleep disturbance, depression, anxiety, and anorexia). (See <a class="local">'Control of physical symptoms'</a> below and <a class="local">'Antidepressants'</a> below.)</p><p></p><p class="bulletIndent1">For patients with cancer-related pain who are receiving opioids, opioid analgesics should be titrated or the schedule/agent modified so as to alleviate pain without causing significant fatigue. If needed, a trial of psychostimulants may help to reverse opioid-related sedation. (See <a class="local">'Patients receiving opioids'</a> below.)</p><p></p><p>Pharmacologic and nonpharmacologic interventions for CRF are discussed in the sections below. Specific recommendations for managing CRF in patients receiving active treatment, cancer survivors, and in terminal patients receiving palliative care are summarized below. (See <a class="local">'Interventions'</a> below.)</p><p>Guidelines for screening, assessment, and management of adults with CRF during and after therapy are available from Canada  (<a class="graphic graphic_table graphicRef94903" href="/d/graphic/94903.html" rel="external">table 2</a>) [<a href="#rid13">13</a>], the Oncology Nursing Society [<a href="#rid14">14</a>], the National Comprehensive Cancer Network (NCCN), and others.</p><p class="headingAnchor" id="H594451919"><span class="h1">INTERVENTIONS</span><span class="headingEndMark"> — </span>Management of CRF involves specific treatment for potentially reversible causes (ie, treating anemia or metabolic or endocrine abnormalities, as well as managing pain, insomnia, depression, or anxiety) and symptomatic measures when no obvious etiology or reversible cause can be identified. Nonspecific symptom-based treatment measures include education, counseling, and pharmacologic (eg, psychostimulants and other wakefulness agents) as well as nonpharmacologic (eg, exercise, yoga, acupuncture) measures.</p><p class="headingAnchor" id="H254671514"><span class="h2">Control of contributory factors</span><span class="headingEndMark"> — </span>If any of the factors known to be associated with fatigue is identified (eg, anemia, hypothyroidism, hypogonadism, sleep disorder, opioid-related sedation), these should be addressed as the initial approach to fatigue. Optimizing management of physical symptoms such as pain, nausea, and dyspnea can help to alleviate fatigue. (See  <a class="medical medical_review" href="/d/html/2802.html" rel="external">"Cancer-related fatigue: Prevalence, screening, and clinical assessment", section on 'Main contributory factors'</a>.)</p><p class="headingAnchor" id="H606308092"><span class="h3">Control of physical symptoms</span><span class="headingEndMark"> — </span>Physical symptoms such as nausea, dyspnea, and pain may be associated with fatigue, particularly in patients with advanced cancer. Optimizing management of these physical symptoms may significantly alleviate fatigue. The benefits of systematic monitoring and treatment of physical symptoms in fatigued patients was shown in a randomized trial in which 152 fatigued patients (fatigue score ≥4 on a numerical rating scale of 0 to 10) with advanced cancer were randomly assigned to protocolized, patient-tailored treatment or usual care [<a href="#rid15">15</a>]. The intervention group consisted of four meetings over a 10-week period with a nurse specialist who coordinated a complex intervention aimed at identifying and treating symptoms of pain, nausea, vomiting, constipation, lack of appetite, shortness of breath, cough, and dry mouth. There were modest but significant improvements over time in favor of the nurse-led intervention for the primary outcome (general fatigue, as assessed by the Multidimensional Fatigue Inventory [MFI]) as well as for secondary outcomes such as level of reduced activity, symptom burden, interference of fatigue with daily life, anxiety, and intensity of fatigue as measured by the 0 to 10 numerical rating scale.</p><p class="headingAnchor" id="H3"><span class="h3">Anemic patients</span><span class="headingEndMark"> — </span>Anemia is the most common reversible cause of CRF, particularly among patients receiving chemotherapy. Correction of anemia has been associated with an improvement in health-related quality of life (QOL) and fatigue [<a href="#rid16">16</a>].</p><p>Optimal management of symptomatic anemia requires an accurate diagnosis to identify potentially remediable causes (eg, ongoing blood loss, hemolysis, iron, <a class="drug drug_general" data-topicid="8475" href="/d/drug information/8475.html" rel="external">folic acid</a>, or <a class="drug drug_general" data-topicid="9302" href="/d/drug information/9302.html" rel="external">vitamin B12</a> deficiency). If a potentially treatable cause cannot be identified, treatment options include red blood cell (RBC) transfusion, or for patients with chemotherapy-related myelosuppression, an erythropoiesis-stimulating agent (ESA). (See  <a class="medical medical_review" href="/d/html/7140.html" rel="external">"Causes of anemia in patients with cancer"</a>.)</p><p class="headingAnchor" id="H10231168"><span class="h4">Transfusions versus ESAs</span><span class="headingEndMark"> — </span>Hemoglobin (Hb) levels can be raised with either erythropoiesis-stimulating agents (ESAs) or red blood cell (RBC) transfusions. The choice between these approaches must be individualized; the risks and benefits of either approach are outlined in the table  (<a class="graphic graphic_table graphicRef78476" href="/d/graphic/78476.html" rel="external">table 3</a>), and discussed in more detail separately. (See  <a class="medical medical_review" href="/d/html/2799.html" rel="external">"Role of erythropoiesis-stimulating agents in the treatment of anemia in patients with cancer", section on 'ESAs versus transfusion'</a>.)</p><p>Various topics related to RBC transfusion, including indications and transfusion thresholds, and complications are discussed in detail in other topics. (See  <a class="medical medical_review" href="/d/html/7948.html" rel="external">"Indications and hemoglobin thresholds for RBC transfusion in adults"</a> and  <a class="medical medical_review" href="/d/html/7932.html" rel="external">"Hemolytic transfusion reactions"</a> and  <a class="medical medical_review" href="/d/html/7947.html" rel="external">"Immunologic transfusion reactions"</a> and  <a class="medical medical_review" href="/d/html/7919.html" rel="external">"Transfusion-associated circulatory overload (TACO)"</a> and  <a class="medical medical_review" href="/d/html/3805.html" rel="external">"Transfusion-transmitted bacterial infection"</a> and  <a class="medical medical_review" href="/d/html/7157.html" rel="external">"Approach to the patient with suspected iron overload", section on 'Transfusional iron overload'</a>.)</p><p>Cancer patients who are being considered for treatment with ESAs as an alternative to RBC transfusion should meet all of the following criteria [<a href="#rid17">17</a>] (see  <a class="medical medical_review" href="/d/html/2799.html" rel="external">"Role of erythropoiesis-stimulating agents in the treatment of anemia in patients with cancer", section on 'Minimal requirements'</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Anemia should be due to chemotherapy treatment for a nonhematologic malignancy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other treatable causes of anemia (eg, blood loss, hemolysis, nutritional deficiency [eg, iron, B12, folate]) should be excluded or treated if present. (See  <a class="medical medical_review" href="/d/html/7133.html" rel="external">"Diagnostic approach to anemia in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An initial hemoglobin level of 10 g/dL or less should be present, although patients with a hemoglobin level between 10 and 11 g/dL who are highly symptomatic can also be considered for ESA therapy on an individual basis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Contraindications to use of an ESA include predisposition to thromboembolism (eg, prior history of thromboses, surgery, prolonged periods of immobilization or limited activity, multiple myeloma treated with an immunomodulatory agent plus an anthracycline or high-dose corticosteroid) or uncontrolled hypertension.</p><p></p><p>However, treatment with RBC transfusions may still be appropriate for patients whose clinical condition indicates the need for immediate correction of the hemoglobin level and for those in whom reducing the frequency of transfusion is not an important consideration. This subject is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/2799.html" rel="external">"Role of erythropoiesis-stimulating agents in the treatment of anemia in patients with cancer", section on 'Clinical use of ESAs in cancer patients'</a>.)</p><p class="headingAnchor" id="H254672248"><span class="h3">Sleep disturbance</span><span class="headingEndMark"> — </span>For patients with insomnia or other sleep disturbance, specific measures to improve sleep hygiene should be suggested  (<a class="graphic graphic_table graphicRef50224" href="/d/graphic/50224.html" rel="external">table 4</a>). Stress reduction and especially psychosocial and behavioral interventions, or integrative medicine approaches such as gentle yoga may help. Patients who do not respond to these measures may require short-term use of medications to help them sleep, but we generally discourage use of these agents, especially for long-term use, in patients with CRF. Complementary/integrative approaches are discussed in more detail below. (See <a class="local">'Mind and body practices'</a> below.)</p><p class="headingAnchor" id="H254671702"><span class="h2">Nonpharmacologic interventions</span></p><p class="headingAnchor" id="H7"><span class="h3">Exercise</span><span class="headingEndMark"> — </span>Unless contraindicated (eg, by the presence of extensive lytic bone metastases, extreme thrombocytopenia, fever or active infection, or safety issues),<strong> </strong>we suggest an individualized program of moderate aerobic exercise for most patients with CRF, both during active treatment and for those who have completed treatment. We agree with guidelines from the American Society of Clinical Oncology (ASCO) for management of adult cancer survivors with fatigue that recommend 150 minutes of moderate aerobic exercise (eg, fast walking, cycling, or swimming) per week, with an additional two to three strength training (eg, weight-lifting) sessions weekly. (See <a class="local">'Recommendations of expert groups'</a> below.)</p><p>Walking programs are generally safe for most cancer survivors; patients can begin this type of program after consulting with their doctors, without any formal exercise testing (eg, a stress test) [<a href="#rid18">18</a>]. Patients at higher risk of injury (ie, those with neuropathy, cardiomyopathy, or other long-term effects of cancer therapy) should be referred to a physical therapist or exercise specialist. Breast cancer survivors with lymphedema should also consider meeting with an exercise specialist before initiating a program of upper-body strength training exercises [<a href="#rid10">10</a>]. (See  <a class="medical medical_review" href="/d/html/738.html" rel="external">"Clinical staging and conservative management of peripheral lymphedema", section on 'Diet and exercise'</a>.)</p><p>To avoid fatigue, cancer patients, particularly those undergoing active treatment, are often advised to rest and downregulate their daily activities. However, because inactivity can induce muscular wasting, prolonged rest can lead to further loss of physical strength and endurance [<a href="#rid19">19</a>]. Although many fatigued patients have difficulty believing that exercise will improve their symptoms, physical exercise training programs can increase functional capacity, leading to reduced effort in performing usual activities and a decreased sense of fatigue [<a href="#rid19">19-23</a>].</p><p>Research on the effects of exercise on CRF includes studies of patients receiving active treatment and those who have completed treatment. Experimental designs vary, sample sizes often are small, and many series are limited to women with breast cancer or men with prostate cancer [<a href="#rid24">24</a>]. The available data on the benefits of exercise in individuals with colorectal cancer are mixed [<a href="#rid25">25-28</a>].</p><p>The type of exercise is also variable, with some studies evaluating walking [<a href="#rid3">3,22,29,30</a>], bicycling [<a href="#rid31">31-33</a>], resistance training [<a href="#rid34">34-37</a>], deep water aquatic exercise [<a href="#rid38">38</a>], or a combined approach [<a href="#rid39">39-42</a>], and still others where the patient was allowed to choose the type of exercise they preferred [<a href="#rid20">20,43</a>]. The recommended exercise programs vary in length from six weeks to six months.</p><p>Regardless of these limitations, all trials and meta-analyses have demonstrated significant benefits (less fatigue and emotional distress, decreased sleep disturbance, improved functional capacity, and better QOL) for moderate exercise in patients with cancer:</p><p class="bulletIndent1"><span class="glyph">●</span>A meta-analysis of nine randomized trials of home-based physical activity (ranging in duration from six weeks to six months, with the majority lasting 11 to 12 weeks) to alleviate fatigue in cancer survivors showed a significant effect in favor of the intervention immediately afterward (standardized mean difference [SMD] 0.22, 95% CI 0.06-0.37), and at three months (SMD 0.27, 95% CI 0.04-0.51) and six to nine months later (SMD 0.31, 95% CI 0.08-0.55) [<a href="#rid44">44</a>]. Interventions that included frequent counseling (every one to three weeks) were associated with larger improvements in fatigue than no or less frequent counseling.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A later systematic review conducted by ASCO [<a href="#rid45">45</a>] noted that meta-analyses in several different types of cancer reported that exercise during cancer treatment led to improvements in cardiorespiratory fitness, strength, fatigue, and other patient reported outcomes [<a href="#rid46">46-53</a>], as well as a moderate reduction in sleep disturbance during cancer treatment [<a href="#rid54">54</a>]. They concluded that oncology providers should recommend aerobic and resistance exercise during active cancer treatment with curative intent to mitigate the side effects of treatment. However, the current evidence does not allow specific recommendations as to the specific duration or intensity of exercise during treatment required to favorably affect outcomes. The frequency of adverse events during exercise appears to be low.</p><p></p><p>Improved levels of meaningful and effective physical activity may be facilitated by the use of printed materials, supervised exercise programs, a step pedometer, or a combination of these approaches, rather than a simple recommendation to perform increased activity [<a href="#rid55">55,56</a>]. Specific exercise programs should be preceded by a careful evaluation of comorbidities and exercise contraindications (such as extensive lytic bone metastases, extreme thrombocytopenia). The prescribed exercise program should be individualized and take into consideration the patient's age, sex, type of cancer and treatment, and the patient's physical fitness level. The initial intensity and duration of exercise should be low and slowly increased, as the patient's medical condition allows. Pool activities are an especially good form of physiotherapy.</p><p>However, neutropenic patients must avoid environments where the risk of exposure to infectious agents is high (eg, public swimming pools).</p><p>Barriers to exercise include physical and disease-related limitations, lack of time/interest/motivation/facilities, and lack of encouragement from family and friends [<a href="#rid10">10</a>]. Younger patients with limited or cured disease may be more motivated to engage in exercise programs than older patients or those with advanced disease or restrictive comorbidities.</p><p class="headingAnchor" id="H1095521342"><span class="h4">Pre-exercise cardiovascular testing</span><span class="headingEndMark"> — </span>Cancer patients are often older, and they may either have overt cardiovascular disease or be at risk for developing cardiovascular disease. Furthermore, direct and indirect effects of anticancer treatment may compound other risks. As a result of these issues, cancer patients may be at heightened risk for a cardiovascular event. (See  <a class="medical medical_review" href="/d/html/7062.html" rel="external">"Cardiotoxicity of radiation therapy for breast cancer and other malignancies"</a> and  <a class="medical medical_review" href="/d/html/774.html" rel="external">"Cardiotoxicity of trastuzumab and other HER2-targeted agents"</a> and  <a class="medical medical_review" href="/d/html/90854.html" rel="external">"Clinical manifestations, diagnosis, and treatment of anthracycline-induced cardiotoxicity"</a> and  <a class="medical medical_review" href="/d/html/2812.html" rel="external">"Cardiotoxicity of cancer chemotherapy agents other than anthracyclines, HER2-targeted agents, and fluoropyrimidines"</a>.)</p><p>Pre-exercise clearance is not required for the majority of cancer patients who are planning to initiate an exercise program, screening should be considered for high-risk populations, including those with diabetes and multiple risk factors for coronary heart disease, including prior mediastinal irradiation or anthracycline use. (See  <a class="medical medical_review" href="/d/html/1519.html" rel="external">"Screening for coronary heart disease", section on 'Recommendations from major societies'</a>.).</p><p class="headingAnchor" id="H2355987218"><span class="h4">Recommendations of expert groups</span><span class="headingEndMark"> — </span>Guidelines from ASCO for management of adult cancer survivors with fatigue, recommend 150 minutes of moderate aerobic exercise (eg, fast walking, cycling, or swimming) per week, with an additional two to three strength training (eg, weight lifting) sessions weekly [<a href="#rid10">10</a>]. A later guideline also recommends exercise in patients undergoing active anticancer treatment [<a href="#rid45">45</a>]. Likewise, guidelines from the European Society of Medical Oncology (ESMO) also recommend physical exercise of moderate intensity and aerobic and functional resistance exercises for non-cachectic patients with cancer [<a href="#rid57">57</a>].</p><p class="headingAnchor" id="H254672117"><span class="h3">Mind and body practices</span><span class="headingEndMark"> — </span>For most patients with CRF both during active treatment and after treatment is completed, we suggest some form of cognitive-behavioral intervention. Patients undergoing active anticancer treatment should be offered advice on general strategies that can help to manage fatigue and guidance on self-monitoring of fatigue levels. Specific suggestions to conserve energy during activities of daily living are outlined in the tables  (<a class="graphic graphic_table graphicRef73183" href="/d/graphic/73183.html" rel="external">table 5</a> and <a class="graphic graphic_table graphicRef53415" href="/d/graphic/53415.html" rel="external">table 6</a>). For patients undergoing active anticancer treatment and for survivors, cognitive behavioral therapy and mind-body practices such as yoga, acupuncture, Tai chi, or mindfulness-based approaches may also be of benefit, if patients are interested in these approaches, and practitioners are available.</p><p>These recommendations are consistent with guidelines for treatment of CRF from ESMO [<a href="#rid57">57</a>] and ASCO guidelines on management of fatigue in cancer survivors [<a href="#rid10">10</a>].</p><p>Mind and body practices (MBPs) refer to a group of complementary/integrative therapies that share a common perspective: emphasizing the potential value of training the "mind" (by shifting cognitions and/or creating a desirable emotional state) in a way that favorably influences bodily functions. Many of these treatments require a competent and specifically trained health professional. An overview of these approaches, which includes information on training, credentialing, and licensure is provided separately. (See  <a class="medical medical_review" href="/d/html/2831.html" rel="external">"Overview of complementary, alternative, and integrative medicine practices in oncology care, and potential risks and harm"</a>.)</p><p class="headingAnchor" id="H3535520028"><span class="h4">Cognitive-behavioral interventions</span></p><p class="headingAnchor" id="H3140283651"><span class="h5">Active cancer treatment</span><span class="headingEndMark"> — </span>Multiple small randomized trials and a meta-analysis of 77 trials indicate that a variety of nonpharmacologic psychosocial and behavioral interventions are effective for improving CRF in patients receiving active cancer treatment [<a href="#rid58">58-66</a>], and its benefits have been shown to persist for at least two years after intervention [<a href="#rid67">67</a>]. However, not all data have been consistent. A meta-analysis of 12 randomized clinical trials (Cochrane review) enrolling patients undergoing cancer treatment with palliative intent for incurable cancer suggested no benefit from nonpharmacologic strategies [<a href="#rid68">68</a>]. Variations in methodologies of included studies, as well as patients enrolled, may account for differences in results of this meta-analysis and previous studies. For example, the Cochrane meta-analysis included only patients receiving treatment for incurable cancer. It is conceivable that such patients would not benefit from these interventions, whereas patients being treated with curative intent and long-term survivors may be more likely to derive some benefit.</p><p>Furthermore, whether all patients require formal psychosocial and behavioral intervention by a psychologist or psychiatrist in order to benefit from psychosocial interventions is unclear, and to the extent that fatigue has a physiologic basis, cognitive-behavioral interventions may not be effective in all patients. In a randomized study that included 115 patients receiving radiation therapy (RT) for advanced cancer, a structured multidisciplinary program that included cognitive, emotional, physical, social, and spiritual interventions did not prevent the development of fatigue [<a href="#rid69">69</a>], even though it was associated with an improvement in QOL [<a href="#rid70">70</a>].</p><p class="headingAnchor" id="H2614151545"><span class="h5">Cancer survivors</span><span class="headingEndMark"> — </span>Randomized trials, systematic reviews, and meta-analyses demonstrate that cognitive/behavioral interventions can also reduce fatigue in posttreatment survivors [<a href="#rid67">67,71-74</a>], and the benefits seem to be maintained with long-term follow-up [<a href="#rid67">67</a>].</p><p class="headingAnchor" id="H1609234415"><span class="h5">Type of intervention</span><span class="headingEndMark"> — </span>An example of a simple program of cognitive-behavioral intervention with specific adaptive strategies for management of symptoms such as fatigue is available  (<a class="graphic graphic_table graphicRef54322" href="/d/graphic/54322.html" rel="external">table 7</a>) [<a href="#rid75">75</a>]. Patients should prioritize and pace activities in an attempt to conserve energy and delegate tasks to others, if feasible [<a href="#rid76">76</a>]. Nonessential activities should be postponed if moderate or severe fatigue is present. Daily self-monitoring in a treatment log or diary may help to identify peak energy periods and the effectiveness of specific interventions. Participation and incorporating family members in activities that are specifically designed to distract from the sense of fatigue (eg, card-playing, visiting) may be useful [<a href="#rid77">77-79</a>].</p><p>Structured support groups are helpful for some patients [<a href="#rid80">80-83</a>], although others may benefit from individual counseling for stress management, depression, and anxiety [<a href="#rid61">61,84-86</a>]; stress management/relaxation training [<a href="#rid87">87-90</a>]; or comprehensive programs that enhance coping skills through formal psychosocial and behavioral interventions [<a href="#rid65">65,75,91-93</a>].</p><p>The benefits of a combined approach to psychosocial and behavioral interventions were studied in a trial in which 273 survivors with moderate to severe CRF (≥4 on item 3 of the Brief Fatigue Inventory [BFI]  (<a class="graphic graphic_table graphicRef54810" href="/d/graphic/54810.html" rel="external">table 8</a>)) who had completed primary cancer treatment within the past 24 months were randomly assigned to a 12-week individually tailored CRF program versus routine care [<a href="#rid94">94</a>]. The intervention, which was based upon NCCN guidelines for management of CRF, consisted of internet-based educational information covering six strategic areas of energy conservation, physical activity, nutrition, sleep hygiene, pain control, and distress management, as well as a general introduction to CRF that allowed individual patients to evaluate their CRF status. Patients were assessed at baseline and at 12 weeks with the BFI  (<a class="graphic graphic_table graphicRef54810" href="/d/graphic/54810.html" rel="external">table 8</a>) and Fatigue Severity Scale (FSS; ranked on a seven-point scale) for the primary outcome, and the Hospital Anxiety and Depression Scale (HADS) and the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30) for secondary outcomes.</p><p>Patients who received the cognitive behavioral intervention had a significantly greater decrease in BFI global score (-0.66, 95% CI -1.04 to -0.27) and FSS total score (-0.49, 95% CI -0.78 to -0.21) from baseline, although the clinical meaningfulness of these small differences is unclear. The intervention group also experienced a significantly greater decrease in HADS score and significantly greater increase in global QOL, but the differences were also small and of unclear clinical meaningfulness.</p><p>Further study of educational interventions in a variety of cancer patients (those under current treatment with differing interventions, those without evidence of malignancy and on no treatment, etc) and in different geographical and cultural environments is necessary to determine the impact of any educational intervention on CRF in these different settings.</p><p>Although a variety of cognitive-behavioral and psychosocial interventions can be beneficial, discovering which patients benefit from what type of psychosocial intervention is an unresolved issue [<a href="#rid95">95</a>]. There are no randomized trials comparing different approaches, and as noted above, it is not clear that all patients require referral to a psychologist for formal psychosocial and behavioral intervention. The challenge to the practitioner is to match the characteristics of individual patients with the most helpful and cost-effective interventions. If possible, patients should be referred to psychosocial service providers specializing in cancer and trained to deliver empirically-based interventions [<a href="#rid10">10</a>].</p><p class="headingAnchor" id="H254672482"><span class="h4">Meditation and mindfulness-based approaches</span><span class="headingEndMark"> — </span>For cancer survivors with persistent fatigue, we suggest mindfulness-based approaches such as mindfulness-based stress reduction (MBSR).</p><p>The term "meditation" is an umbrella term that covers a large number of traditions and practices with specific evidence on their effectiveness for improved symptom management and ability to improve the stress response. They all require an active participant in the meditation; specific training in the ability to "let go" of thoughts, feeling sensations, external distractions; and consistent daily or regular practice. Some examples include mindfulness meditation, transcendental meditation, and Zen meditation. MBSR is a well-defined and systematic patient-centered educational approach which uses relatively intensive training in mindfulness meditation as the core of a program to teach people how to take better care of themselves and live healthier and more adaptive lives. (See  <a class="medical medical_review" href="/d/html/2831.html" rel="external">"Overview of complementary, alternative, and integrative medicine practices in oncology care, and potential risks and harm", section on 'Meditation and mindfulness-based stress reduction'</a>.)</p><p>There is evidence from multiple randomized trials (most of which enrolled fewer than 100 patients) that mindfulness-based approaches such as MBSR may relieve fatigue in cancer survivors [<a href="#rid72">72,96-99</a>]. In the largest trial, 229 women with early-stage breast cancer after surgery, chemotherapy, and radiotherapy were randomly assigned to an eight-week program of mindfulness-based stress reduction or usual care [<a href="#rid97">97</a>]. The intervention group had significant improvements at weeks 8 and 12 in the primary outcome scores on the Profile of Mood States (POMS) scale, which included fatigue.</p><p>Benefit for improving CRF is further supported by at least one meta-analysis, although a second analysis reports mixed benefits for improving sleep quality [<a href="#rid100">100,101</a>].</p><p class="headingAnchor" id="H11096059"><span class="h4">Yoga</span><span class="headingEndMark"> — </span>Yoga is a collection of mind-body practice with origins in ancient South Asian philosophy and practice. It includes physical postures ("asanas"), breathing and relaxation techniques, as well as diet and meditation. (See  <a class="medical medical_review" href="/d/html/2831.html" rel="external">"Overview of complementary, alternative, and integrative medicine practices in oncology care, and potential risks and harm", section on 'Yoga'</a>.)</p><p>There is some evidence from randomized trials and a meta-analysis that mind-body practices such as yoga may improve sleep quality and fatigue; most of the data (six of the nine randomized trials [<a href="#rid102">102-112</a>]) have enrolled cancer survivors with posttreatment fatigue, the majority with breast cancer:</p><p class="bulletIndent1"><span class="glyph">●</span>In the largest trial, 410 patients with breast cancer who reported moderate or severe sleep disruption within 2 to 24 months after completing treatment were randomly assigned to standard care monitoring with or without yoga [<a href="#rid103">103</a>]. The yoga intervention consisted of breathing exercises, 18 gentle Hatha and restorative yoga postures, and meditation, performed twice weekly. After four weeks, yoga participants demonstrated greater improvements compared with baseline in global sleep quality, the primary endpoint. In addition, the yoga group demonstrated a greater reduction in daytime dysfunction, fatigue, and a reduced use of sleep medications (in contrast to the control group, in which use of sleep aids increased) at postintervention compared with standard care participants. In a later analysis, the positive impact of the yoga intervention on CRF was mediated, in part, by the beneficial impacts on overall sleep quality [<a href="#rid113">113</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A meta-analysis of yoga for CRF in patients with breast cancer included 17 trials (2183 patients) [<a href="#rid114">114</a>]. The intervention consisted of a variety of yoga practices, and the supervised classes ranged from 40 to 90 minutes, and took place one to five times weekly for 4 to 24 weeks. The overall risk of bias for the included studies was moderate. For all 17 studies, there was a small but significant effect size for benefit of yoga on change in fatigue scores from baseline (SMD -0.31, 95% CI -0.52 to -0.10). When analyzed according to treatment status, yoga had a large effect in the four studies with only posttreatment patients (SMD -0.80, 95% CI -1.52 to -0.09). By contrast, the effect size was small in the 13 studies of patients undergoing anticancer treatment (SMD -0.25, 95% CI -0.47 to -0.03). The wide confidence intervals imply imprecision in the point estimates.</p><p></p><p class="headingAnchor" id="H9"><span class="h4">Acupuncture</span><span class="headingEndMark"> — </span>Acupuncture appears to be helpful for CRF in cancer survivors; the data are less robust in those with CRF during active cancer therapy. However, given the overall safety of this approach, and the likelihood that benefits outweigh risks, interested patients may be offered a trial of acupuncture if symptoms of moderate to severe fatigue persist despite other forms of therapy, and experienced practitioners are available.</p><p>Benefit from acupuncture has been suggested in several (but not all [<a href="#rid115">115</a>]) randomized trials, mostly with fewer than 100 patients enrolled; some trials were conducted in cancer survivors and some in patients receiving active treatment [<a href="#rid116">116-124</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>In the largest of these trials, 302 patients with nonmetastatic breast cancer who had completed chemotherapy between one month and five years previously, and who were experiencing at least moderate fatigue (score ≥5 on a scale of 0 to 10) were randomly assigned to usual care with and without acupuncture [<a href="#rid118">118</a>]. The usual care group received a booklet with information about fatigue and its management, while the acupuncture group received both the booklet and a once weekly treatment by an acupuncturist (needling three pairs of acupoints) for six weeks. The primary outcome was general fatigue at six weeks, as measured by the MFI. Acupuncture was of significant benefit, with an estimated difference in the week 6 general fatigue score (acupuncture minus control) of -3.11 (95% CI -3.97 to -2.25), given equal baseline scores. Acupuncture also significantly improved other fatigue aspects as measured by the MFI, including physical and mental fatigue, anxiety and depression, and QOL.</p><p></p><p class="bulletIndent1">A major problem with interpreting these results is the lack of a sham acupuncture control group; at least in the setting of noncancer disease such as chronic pain, both acupuncture and sham acupuncture have been shown to have much greater efficacy than no treatment, suggesting a strong placebo effect [<a href="#rid125">125</a>]. </p><p></p><p class="bulletIndent1">Benefit from acupuncture could not be confirmed in a preliminary report of a randomized trial comparing acupuncture versus sham acupuncture in 97 patients with chronic chemotherapy-related fatigue [<a href="#rid115">115</a>]. In both groups, scores on the BFI  (<a class="graphic graphic_table graphicRef54810" href="/d/graphic/54810.html" rel="external">table 8</a>) fell by about one point, and there was no significant difference between groups. The study interpretation was limited by a high number of patients who were lost to follow-up.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>This issue was addressed in a meta-analysis of 10 randomized trials of acupuncture for CRF (1327 patients), in which acupuncture (variably administered for 20 to 30 min/session from one to three times weekly over a period of 2 to 10 weeks) was compared with sham acupuncture (five trials), typical care (eight trials), or American ginseng (one trial) [<a href="#rid126">126</a>]. Acupuncture had a marked effect on CRF, both in cancer survivors (four trials, SMD in BFI scores from baseline to posttreatment -1.38, 95% CI -1.80 to -0.71) and those undergoing active treatment (six trials, SMD -1.16, 95% CI -1.91 to -0.42). Acupuncture successfully mitigated CRF as compared with sham acupuncture, but the effect size was smaller (SMD -0.83, 95% CI -1.27 to -0.39) than when acupuncture was compared with usual care (SMD -1.74, 95% CI -2.74 to -0.74). Seven RCTs reported the occurrence of adverse events, but only one study reported five adverse events (spot bleeding, bruising, discomfort or nausea), none of which were classified as serious [<a href="#rid117">117</a>].</p><p></p><p class="headingAnchor" id="H3434920910"><span class="h4">Hypnosis</span><span class="headingEndMark"> — </span>The role of hypnosis for patients with CRF is unclear, and additional research is needed.</p><p>Hypnosis/hypnotherapy can be defined as an induced state of attentive, focused concentration with suspension of some peripheral awareness; it can be facilitated by a specially trained therapist or practiced on one's own self (self‐hypnosis). (See  <a class="medical medical_review" href="/d/html/2831.html" rel="external">"Overview of complementary, alternative, and integrative medicine practices in oncology care, and potential risks and harm", section on 'Hypnotherapy'</a>.)</p><p>Several small trials of hypnosis as a component of treatment for CRF, as well as a systematic review of hypnosis in breast cancer care, suggest potential benefit for this approach, at least for patients with breast cancer [<a href="#rid65">65,127-131</a>], although the data are sparse and three of the trials combined hypnotherapy with psychosocial and behavioral interventions [<a href="#rid65">65,127,131</a>]. A systematic review of hypnosis in breast cancer care, which included the three trials of hypnotherapy plus psychosocial and behavioral interventions, all of which were conducted in women with breast cancer receiving radiotherapy, concluded that while the intervention improved distress and fatigue more research was needed to assess the benefits of hypnosis.</p><p class="headingAnchor" id="H1870713175"><span class="h4">Tai chi/qigong</span><span class="headingEndMark"> — </span>Tai chi is a subset of qigong, which is a form of ancient and traditional Chinese medicine that integrates movement (physical postures), meditation (focused attention), and controlled breathing. (See  <a class="medical medical_review" href="/d/html/2831.html" rel="external">"Overview of complementary, alternative, and integrative medicine practices in oncology care, and potential risks and harm", section on 'Tai chi/qigong'</a>.)</p><p>Several randomized trials and two meta-analyses suggest potential benefit for Tai chi/qigong in patients with CRF and/or sleep disturbance [<a href="#rid132">132-138</a>]. The larger meta-analysis included 22 studies, including 15 randomized trials (1283 participants) evaluating the benefits of Tai chi/qigong for fatigue, sleep difficulty, depression, pain, and QOL in patients with breast (seven trials), prostate (two trials), or lung cancer (one trial), lymphoma (one trial) or a mix of different cancer types (four trials) [<a href="#rid132">132</a>].The duration of the intervention varied from 3 to 12 weeks. Methodologic bias was described as low in 12 of the randomized trials and high in 3. The following results were noted:</p><p class="bulletIndent1"><span class="glyph">●</span>CRF was assessed in 10 randomized trials; the pooled overall effect size suggested a significant improvement with a medium effect size (effect size [ES] -0.53, 95% CI -0.97 to -0.28, p &lt;0.001).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cancer-related sleep difficulty was assessed in six randomized trials; the pooled analysis suggested a significant small to medium ES (ES -0.49, 95% CI -0.89 to -0.09, p = 0.018).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>QOL was assessed in 12 randomized trials; data from 11 were pooled for analysis. The overall ES favored the intervention with a small ES (ES 0.33, 95% CI 0.10-0.56, p = 0.004).</p><p></p><p>Data are also available from another trial of 90 breast cancer survivors that postdated the meta-analysis; overall, Tai chi was found to be noninferior to psychosocial and behavioral interventions for insomnia [<a href="#rid137">137</a>].</p><p class="headingAnchor" id="H254672885"><span class="h4">Other</span><span class="headingEndMark"> — </span>Biofield therapies (touch therapy, reiki), and other mind-body practices (eg, massage therapy, music therapy, relaxation) may offer some benefit [<a href="#rid139">139-143</a>]; however, additional research, especially in the posttreatment population, is needed before any of these complementary therapies can be routinely recommended [<a href="#rid10">10</a>]. (See  <a class="medical medical_review" href="/d/html/2831.html" rel="external">"Overview of complementary, alternative, and integrative medicine practices in oncology care, and potential risks and harm", section on 'Reiki'</a> and  <a class="medical medical_review" href="/d/html/2831.html" rel="external">"Overview of complementary, alternative, and integrative medicine practices in oncology care, and potential risks and harm", section on 'Relaxation therapy and stress management'</a> and  <a class="medical medical_review" href="/d/html/2831.html" rel="external">"Overview of complementary, alternative, and integrative medicine practices in oncology care, and potential risks and harm", section on 'Music therapy'</a>.)</p><p class="headingAnchor" id="H159822173"><span class="h4">Clinical practice guidelines</span><span class="headingEndMark"> — </span>A year 2017 clinical practice guideline on the use of integrative therapies in patients during and after breast cancer treatment from the Society for Integrative Oncology (SIO) rated the strength of available evidence for each integrative modality based upon a modified version of the recommendations of the US Preventive Services Task Force [<a href="#rid144">144</a>]. They emphasized the lack of A- or B-graded (ie, high-quality) integrative therapies for cancer- and cancer treatment-associated fatigue. Hypnosis for improving fatigue during treatment, and acupuncture and yoga for improving posttreatment fatigue all received a "C" grade (weak evidence of benefit) due primarily to a lack of multiple large trials. The authors concluded that these modalities could be offered or recommended to selected patients based on the understanding that they may bring a small benefit, and that in most cases, the benefits outweighed the risks. There was insufficient evidence on the benefit of other mind-body interventions, including MBSR, to form a clinical recommendation.</p><p>These guidelines were subsequently endorsed by ASCO in 2018 [<a href="#rid145">145</a>].</p><p class="headingAnchor" id="H10"><span class="h2">Pharmacologic management</span><span class="headingEndMark"> — </span>Double-blinded trials are essential to prove benefit from any type of pharmacologic intervention in view of the subjective nature of fatigue and the demonstrated therapeutic effect from placebo in at least two double-blind trials [<a href="#rid146">146,147</a>]. Almost all of the randomized trials addressing pharmacologic management of CRF have been conducted in patients receiving active cancer treatment.</p><p class="headingAnchor" id="H74068150"><span class="h3">Psychostimulants and other wakefulness agents</span><span class="headingEndMark"> — </span>For patients with severe fatigue (BFI, question #3 &gt;7) during cancer therapy in whom nonpharmacologic methods are not helpful, and anemia and other medical conditions and symptoms causing fatigue are controlled, we suggest a therapeutic trial of a psychostimulant or other wakefulness agent (<a class="drug drug_general" data-topicid="9638" href="/d/drug information/9638.html" rel="external">methylphenidate</a>, <a class="drug drug_general" data-topicid="8667" href="/d/drug information/8667.html" rel="external">dexmethylphenidate</a>, or <a class="drug drug_general" data-topicid="10157" href="/d/drug information/10157.html" rel="external">modafinil</a>), although the studies supporting efficacy have reached variable conclusions. Another group of patients that may benefit from the use of psychostimulants are those with opioid-related sedation. Benefit is less certain in patients with mild-to-moderate fatigue during treatment and in those who have completed cancer treatment and have persistent fatigue, but a therapeutic trial is also reasonable if no potentially reversible contributory factors are identified and nonpharmacologic methods are not helpful. (See <a class="local">'Nonpharmacologic interventions'</a> above.)</p><p>These recommendations are consistent with those of ASCO [<a href="#rid10">10</a>] and ESMO, although guidelines from ESMO suggest not using <a class="drug drug_general" data-topicid="10157" href="/d/drug information/10157.html" rel="external">modafinil</a> for treatment of CRF given the mixed results of clinical trials [<a href="#rid57">57</a>].</p><p>Starting doses of <a class="drug drug_general" data-topicid="10157" href="/d/drug information/10157.html" rel="external">modafinil</a> are usually 100 to 200 mg in the morning and again at noon. The maximum daily dose is 400 mg. For <a class="drug drug_general" data-topicid="9638" href="/d/drug information/9638.html" rel="external">methylphenidate</a>, we suggest starting with 5 mg in the morning and 5 mg at noon, titrating as necessary; the maximal dose with the potential for benefit in CRF is 40 mg daily.</p><p>A benefit for psychostimulants in patients with CRF was suggested in a year 2010 Cochrane review [<a href="#rid148">148</a>] of five trials, in which four used <a class="drug drug_general" data-topicid="9638" href="/d/drug information/9638.html" rel="external">methylphenidate</a> and one used <a class="drug drug_general" data-topicid="9341" href="/d/drug information/9341.html" rel="external">dextroamphetamine</a> [<a href="#rid146">146,149-152</a>]. There was a small but statistically significant improvement in fatigue score relative to placebo (standardized mean difference [SMD] in fatigue score -0.28, 95% CI -0.48 to -0.09). However, the results of these and other trials published since the meta-analysis have been mixed, with most failing to demonstrate a statistically significant benefit over placebo.</p><p class="headingAnchor" id="H11"><span class="h4">Methylphenidate and dexmethylphenidate</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9638" href="/d/drug information/9638.html" rel="external">Methylphenidate</a> is a central nervous system stimulant that is structurally related to amphetamines, with a short half-life and a rapid onset of action. Both the pharmacologic properties and clinical efficacy as a central nervous system stimulant reside in the d-isomer, which is available clinically as a distinct drug (<a class="drug drug_general" data-topicid="8667" href="/d/drug information/8667.html" rel="external">dexmethylphenidate</a>, Focalin) and effective at approximately one-half the dose of methylphenidate.</p><p>Of at least eight published randomized controlled trials [<a href="#rid146">146,149,151-156</a>], only two [<a href="#rid149">149,155</a>] have concluded that <a class="drug drug_general" data-topicid="9638" href="/d/drug information/9638.html" rel="external">methylphenidate</a> has a significantly better impact than placebo on CRF. The following represents the range of findings:</p><p class="bulletIndent1"><span class="glyph">●</span>In an early trial, 112 patients with a fatigue score of at least 4 on a scale of 0 to 10 were randomly assigned to 5 mg of <a class="drug drug_general" data-topicid="9638" href="/d/drug information/9638.html" rel="external">methylphenidate</a> or placebo, with patients able to repeat dosing as needed every two hours to a maximum of four tablets per day [<a href="#rid146">146</a>]. Patient-reported fatigue intensity improved over baseline by day 8 in both the methylphenidate- and placebo-treated patients. Thereafter, patients were given the option of receiving open-label methylphenidate. In the open-label phase, the lower fatigue intensity was maintained through day 36.</p><p></p><p class="bulletIndent1">Within the constraints of a very early endpoint, this study could not identify clinical benefits that were attributable to treatment with <a class="drug drug_general" data-topicid="9638" href="/d/drug information/9638.html" rel="external">methylphenidate</a> and suggested that the observed benefits might be in part because of daily contact with the study nurse as well as a possible placebo effect. This is consistent with observations from other randomized trials that patients with CRF can benefit from active psychosocial intervention. (See <a class="local">'Cognitive-behavioral interventions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A lack of benefit for <a class="drug drug_general" data-topicid="9638" href="/d/drug information/9638.html" rel="external">methylphenidate</a> (and from a nursing telephone intervention) was also shown in a later randomized phase II trial involving 142 patients with advanced cancer and a fatigue score of at least 4 on a scale of 0 to 10 [<a href="#rid154">154</a>]. Patients were randomly assigned to one of four groups: methylphenidate (5 mg orally every two hours up to 20 mg daily up to 14 days) plus a nursing telephone intervention (four to six phone calls by a nurse trained in palliative care over a 14-day period focusing on symptom assessment, medication review, psychosocial support, and education), placebo plus the intervention, methylphenidate with a control telephone intervention (nontherapeutic calls conducted by a nonprofessional providing neither support nor education), or placebo plus a control telephone intervention. At the end of 14 days, median scores on the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) subscale improved from baseline in all groups, and there were no significant differences among the groups, leading the authors to conclude that methylphenidate and nursing telephone intervention, either alone or combined, were not superior to placebo in improving CRF. Several cancer-related symptoms were significantly improved in the nursing telephone intervention group compared with those receiving the control telephone intervention (including fatigue, nausea, depression, anxiety, drowsiness, appetite, and feeling of well-being).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>On the other hand, benefit for <a class="drug drug_general" data-topicid="8667" href="/d/drug information/8667.html" rel="external">dexmethylphenidate</a> was suggested in a randomized phase II trial in which 152 patients who received ≥4 cycles of chemotherapy and had persistent fatigue and cognitive impairment at least two months after treatment were randomly assigned to dexmethylphenidate (5 mg twice daily or as needed up to 20 mg daily) or placebo [<a href="#rid149">149</a>]. After eight weeks, the use of dexmethylphenidate was associated with a significant improvement in fatigue but not cognitive function.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Benefit for <a class="drug drug_general" data-topicid="9638" href="/d/drug information/9638.html" rel="external">methylphenidate</a> was also suggested in a very small trial of 30 hospice patients (one each with chronic obstructive pulmonary disease and cirrhosis, the rest cancer) who had fatigue scores of at least 4 on a scale of 0 to 10, and who were assigned to methylphenidate (initial dose 5 mg at 8 AM and 1 PM and titrated every three days according to response and adverse effects) or placebo [<a href="#rid155">155</a>]. Patients taking methylphenidate were found to have significantly lower fatigue scores at day 14 compared with baseline, while there was no improvement in those assigned to placebo.</p><p></p><p>Some of this discrepancy in outcomes could be related to dose. The single positive <a class="drug drug_general" data-topicid="8667" href="/d/drug information/8667.html" rel="external">dexmethylphenidate</a> study used a high mean daily dose (27.7 mg) of dexmethylphenidate (which is about twice as active, mg for mg, as <a class="drug drug_general" data-topicid="9638" href="/d/drug information/9638.html" rel="external">methylphenidate</a>) [<a href="#rid149">149</a>], while the second positive study titrated the dose of methylphenidate over the course of two weeks with a mean effective dose of 10 mg on day 3 and 20 mg on day 14 [<a href="#rid155">155</a>]. One negative study used a relatively small dose of methylphenidate (average daily consumption 6.4 mg per day) [<a href="#rid154">154</a>]. However, another trial, delivering 27 mg per day of dexmethylphenidate, failed to show any benefit for treatment over placebo [<a href="#rid153">153</a>].</p><p>Another potential explanation for these discrepant results is the heterogeneity inherent in the populations studied in these trials. Subset analysis of at least one trial concluded that there might be benefit for <a class="drug drug_general" data-topicid="9638" href="/d/drug information/9638.html" rel="external">methylphenidate</a> in patients presenting with more severe fatigue or more advanced disease [<a href="#rid153">153</a>]. Similar findings have been reported with <a class="drug drug_general" data-topicid="10157" href="/d/drug information/10157.html" rel="external">modafinil</a>. (See <a class="local">'Modafinil'</a> below.)</p><p>Finally, benefit from drugs such as these may depend on the underlying mechanism by which CRF has been generated [<a href="#rid157">157</a>]. A greater understanding of the pathophysiology of CRF may lead to the identification of subtypes that are more responsive to specific treatments. As an example, patients with opioid-related fatigue may benefit from <a class="drug drug_general" data-topicid="9638" href="/d/drug information/9638.html" rel="external">methylphenidate</a> [<a href="#rid158">158</a>]. (See  <a class="medical medical_review" href="/d/html/2800.html" rel="external">"Prevention and management of side effects in patients receiving opioids for chronic pain", section on 'Psychostimulants'</a>.)</p><p class="headingAnchor" id="H12"><span class="h4">Dextroamphetamine</span><span class="headingEndMark"> — </span>Benefit could not be shown for dexamphetamine (10 mg twice daily) in the only placebo-controlled trial involving 50 fatigued patients with advanced cancer who were receiving palliative care [<a href="#rid150">150</a>]. However, the short duration of treatment (eight days), poor performance status of the group as a whole (the majority were Eastern Cooperative Oncology Group [ECOG] performance status 3  (<a class="graphic graphic_table graphicRef72901" href="/d/graphic/72901.html" rel="external">table 9</a>)), and the wide array of other neurologically active medications being administered could all have contributed to the negative result.</p><p class="headingAnchor" id="H13"><span class="h4">Modafinil</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10157" href="/d/drug information/10157.html" rel="external">Modafinil</a>, a nonamphetamine "wake-promoting agent," is used for the treatment of narcolepsy. Limited experience in cancer patients suggests that modafinil is well tolerated, but the data on efficacy for CRF from randomized trials are mixed [<a href="#rid159">159-162</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>In a randomized trial, 867 patients reporting any level of fatigue during chemotherapy (a value of &gt;1 on a BFI scale 0 to 10, item 3  (<a class="graphic graphic_table graphicRef54810" href="/d/graphic/54810.html" rel="external">table 8</a>)) were randomly assigned to <a class="drug drug_general" data-topicid="10157" href="/d/drug information/10157.html" rel="external">modafinil</a> (200 mg daily) or placebo [<a href="#rid161">161</a>]. In an analysis of 631 patients with evaluable data, modafinil significantly reduced fatigue only for the subgroup of patients with high baseline fatigue (BFI item 3 score ≥7  (<a class="graphic graphic_table graphicRef54810" href="/d/graphic/54810.html" rel="external">table 8</a>)), while there were no significant differences in patients with mild to moderate fatigue at baseline. Modafinil did not improve depression, reinforcing the view that depression and CRF are not linked.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Benefit in patients with severe fatigue could not be confirmed in a later trial in which 208 adults with locally advanced or metastatic lung cancer and severe fatigue (score ≥5 out of 10) were randomly assigned to <a class="drug drug_general" data-topicid="10157" href="/d/drug information/10157.html" rel="external">modafinil</a> or a matched placebo (100 mg daily for 14 days, then 200 mg daily for 14 days) [<a href="#rid162">162</a>]. In an intention-to-treat analysis of the 160 patients who completed questionnaires at both baseline and day 28, both modafinil and placebo led to a clinically significant five-point improvement in the FACIT-F subscale, and there was no difference between the two groups.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The benefits of <a class="drug drug_general" data-topicid="10157" href="/d/drug information/10157.html" rel="external">modafinil</a> were not addressed in the above-mentioned meta-analysis [<a href="#rid148">148</a>]. (See <a class="local">'Psychostimulants and other wakefulness agents'</a> above.)</p><p></p><p class="headingAnchor" id="H10231194"><span class="h3">Testosterone for hypogonadal men</span><span class="headingEndMark"> — </span>We suggest a therapeutic trial of <a class="drug drug_general" data-topicid="9981" href="/d/drug information/9981.html" rel="external">testosterone</a> supplementation in men with fatigue who are found to have hypogonadism.</p><p>Hypogonadism affects two-thirds of men with advanced cancer. Previous studies have shown that low <a class="drug drug_general" data-topicid="9981" href="/d/drug information/9981.html" rel="external">testosterone</a> levels in men with cancer are associated with fatigue, anorexia, depression, insomnia, and diminished physical function [<a href="#rid163">163,164</a>]. (See  <a class="medical medical_review" href="/d/html/7462.html" rel="external">"Clinical features and diagnosis of male hypogonadism"</a> and  <a class="medical medical_review" href="/d/html/7460.html" rel="external">"Causes of secondary hypogonadism in males"</a>.)</p><p><a class="drug drug_general" data-topicid="9981" href="/d/drug information/9981.html" rel="external">Testosterone</a> replacement improves QOL and diminishes fatigue in patients with noncancer conditions. (See  <a class="medical medical_review" href="/d/html/7461.html" rel="external">"Testosterone treatment of male hypogonadism", section on 'Clinical benefits of testosterone therapy in hypogonadal men'</a>.)</p><p>The benefit of <a class="drug drug_general" data-topicid="9981" href="/d/drug information/9981.html" rel="external">testosterone</a> replacement for treatment of fatigue in hypogonadal men with advanced cancer has been addressed in the following studies:</p><p class="bulletIndent1"><span class="glyph">●</span>In a small double-blind placebo-controlled trial in which 16 patients treated with placebo and 13 patients treated with <a class="drug drug_general" data-topicid="9981" href="/d/drug information/9981.html" rel="external">testosterone</a> (weight-based intramuscular testosterone administered every 14 days to achieve a bioavailable testosterone level 70 to 270 ng/dL) were evaluable for the primary outcome at day 29 [<a href="#rid165">165</a>]. No statistically significant difference was found for FACIT-F total scores between arms, but sexual desire inventory scores and performance status were better with supplementation. In addition, fatigue subscale scores were significantly better in the testosterone group by day 72. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Benefit was also shown in a randomized phase II study comparing <a class="drug drug_general" data-topicid="9981" href="/d/drug information/9981.html" rel="external">testosterone</a> versus no testosterone in 60 men with advanced renal cell cancer receiving targeted therapy with <a class="drug drug_general" data-topicid="10305" href="/d/drug information/10305.html" rel="external">sunitinib</a> or <a class="drug drug_general" data-topicid="9524" href="/d/drug information/9524.html" rel="external">pazopanib</a> who had low total testosterone levels (&lt;12.1 nmol/L) and no evidence of hypothyroidism [<a href="#rid166">166</a>]. Fatigue scores dropped from a mean of 37 to 20.3 from baseline to day 28 in the supplemented group, whereas they increased from 35.3 to 42.5 in the control group. The difference in fatigue score at day 28 between groups was statistically significant (22.5 points, 95% CI 18.4-22.6), and improvements in quality of life were also observed.</p><p></p><p class="headingAnchor" id="H594452048"><span class="h3">Patients receiving opioids</span><span class="headingEndMark"> — </span>For patients with fatigue and cancer-related pain who are receiving opioids, opioid analgesics should be titrated or the schedule/agent modified so as to alleviate pain without significantly altering mentation. If needed, a trial of psychostimulants may help to reverse opioid-related sedation. (See <a class="local">'Control of contributory factors'</a> above and  <a class="medical medical_review" href="/d/html/2800.html" rel="external">"Prevention and management of side effects in patients receiving opioids for chronic pain", section on 'Somnolence and mental clouding'</a>.)</p><p class="headingAnchor" id="H14"><span class="h3">Antidepressants</span><span class="headingEndMark"> — </span>We suggest a therapeutic trial of an antidepressant in patients with fatigue accompanied by depression. (See  <a class="medical medical_review" href="/d/html/4853.html" rel="external">"Management of psychiatric disorders in patients with cancer", section on 'Pharmacotherapy'</a>.)</p><p>At least three placebo-controlled, randomized trials (and a Cochrane review [<a href="#rid148">148</a>]) in patients undergoing cancer treatment have failed to demonstrate any improvement in fatigue in patients randomly assigned to receive an antidepressant (<a class="drug drug_general" data-topicid="9743" href="/d/drug information/9743.html" rel="external">paroxetine</a>, <a class="drug drug_general" data-topicid="9886" href="/d/drug information/9886.html" rel="external">sertraline</a>) [<a href="#rid167">167-169</a>].</p><p>However, antidepressants may be helpful when a patient has both fatigue and depression [<a href="#rid169">169</a>]. For patients who also have insomnia, <a class="drug drug_general" data-topicid="9711" href="/d/drug information/9711.html" rel="external">nortriptyline</a> or <a class="drug drug_general" data-topicid="8605" href="/d/drug information/8605.html" rel="external">amitriptyline</a> are good choices. Case reports suggest efficacy for <a class="drug drug_general" data-topicid="9171" href="/d/drug information/9171.html" rel="external">bupropion</a> in patients with chronic fatigue syndrome, also known as myalgic encephalomyelitis/chronic fatigue syndrome, but no data are available in patients with CRF.</p><p class="headingAnchor" id="H15"><span class="h3">Glucocorticoids</span><span class="headingEndMark"> — </span>For patients who are in the terminal phase of their illness who have a high symptom burden that includes fatigue, we suggest a trial of glucocorticoid therapy.</p><p>Glucocorticoids such as <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> may be beneficial for patients with CRF [<a href="#rid170">170,171</a>], but data are limited. In a meta-analysis including three randomized controlled trials in 165 patients with advanced cancer and fatigue, the small improvement in fatigue observed with dexamethasone versus placebo after one week did not reach statistical significance; one trial showed that both <a class="drug drug_general" data-topicid="10157" href="/d/drug information/10157.html" rel="external">modafinil</a> and dexamethasone improved fatigue after two weeks relative to baseline, but there were no differences compared with each other [<a href="#rid172">172</a>]. (See <a class="local">'Modafinil'</a> above.)</p><p>As an example of one of the trials included in the meta-analysis, 84 patients with advanced cancer and three or more symptoms related to CRF (fatigue, pain, nausea, loss of appetite, depression, anxiety, or sleep disturbance) of severity ≥4 of 10 on the Edmonton Symptom Assessment Scale  (<a class="graphic graphic_table graphicRef65702" href="/d/graphic/65702.html" rel="external">table 10</a>) were randomly assigned to <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> (4 mg orally twice daily) or placebo [<a href="#rid171">171</a>]. At the end of 14 days, dexamethasone was associated with a significantly better mean improvement of FACIT-F fatigue subscale scores compared with placebo at both day 8 and day 15, and a significantly better mean improvement in FACIT-F total QOL scores at day 15. Within the short time frame of this study, there were no significant differences in the frequency or severity of adverse effects seen with dexamethasone as compared with placebo.</p><p>In a separate, prospective, observational study of 179 patients with metastatic or locally advanced cancer, independent factors predicting improvement in CRF with steroids were higher levels of fatigue (greater than 5 on a 0 to 10 scale), better overall general condition (Palliative Performance Scale score greater than 40), absence of drowsiness, and lack of either ascites or pleural effusion [<a href="#rid173">173</a>].</p><p>However, glucocorticoid side effects limit their long-term use. As such, steroids may be most helpful for patients with CRF who are in the terminal phase of advanced cancer. Dose management is important, as this class of drugs may induce insomnia and/or behavioral changes. These subjects are discussed in more detail separately. (See  <a class="medical medical_review" href="/d/html/14239.html" rel="external">"Overview of fatigue in palliative care", section on 'Glucocorticoids'</a> and  <a class="medical medical_review" href="/d/html/7988.html" rel="external">"Major adverse effects of systemic glucocorticoids"</a>.)</p><p class="headingAnchor" id="H12233080"><span class="h3">Complementary/integrative approaches</span></p><p class="headingAnchor" id="H24908748"><span class="h4">Ginseng and guarana</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ginseng</strong> – For patients who have moderate-to-severe fatigue who are undergoing active anticancer therapy, a therapeutic trial of American or Korean red ginseng is reasonable, as long as the patient is not receiving drugs that may interact unfavorably with ginseng, such as anticoagulants.</p><p></p><p class="bulletIndent1">A benefit for <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fmedlineplus.gov%2Fdruginfo%2Fnatural%2F967.html&amp;token=d5ngiCbB8xFYJWkFI1xcekh7CTTcVcbY3fVxLXEvc7R%2F1D22W2Xd3HUFwcxXTYTGsR%2BbwVaoXMHywGr8%2BzePnw%3D%3D&amp;TOPIC_ID=2813" target="_blank">American ginseng</a> was initially suggested in a pilot study conducted by the North Central Cancer Treatment Group (NCCTG) [<a href="#rid174">174</a>]. A subsequent double-blind trial randomly assigned 364 patients with cancer undergoing or having completed curative-intent therapy and who had a fatigue score of 4 or more (on a scale of 0 to 10) for at least one month to placebo or ginseng (2000 mg daily of a pure ground product) [<a href="#rid175">175</a>]. Patients assigned to ginseng had significantly better scores on the general subscale of the Multidimensional Fatigue Symptom Inventory short-form (MFSI-SF) at eight weeks (change score from baseline 20 versus 10.3 in the placebo group, p = 0.003); the difference was not significant at four weeks (change score from baseline 14.4 versus 8.2). Use of ginseng was also associated with significant improvements in the physical subscale and the total score of the MFSI-SF at eight (but not four) weeks, and in the fatigue inertia subscale of the POMS, but not the vigor activity subscale. Greater benefit was reported in patients receiving active cancer treatment as compared with those who had completed treatment. There were no discernible toxicities associated with treatment.</p><p></p><p class="bulletIndent1">Benefit for Korean red ginseng (KRG, a processed product of Asian ginseng [panax ginseng]) was also shown in a double-blind trial in which 438 patients receiving oxaliplatin-containing chemotherapy for colorectal cancer either in the adjuvant or metastatic disease setting were randomly assigned to KRG (1000 mg orally twice daily) or an identical appearing placebo for 16 consecutive weeks concurrent with chemotherapy [<a href="#rid176">176</a>]. The primary endpoint was the mean change in the area under the curve (AUC) of the Brief Fatigue Inventory (BFI) from baseline over 16 weeks, with higher AUC levels indicative of a greater improvement in fatigue. At 16 weeks, KRG improved CRF compared with placebo, but the differences were significant only in "mood" and "walking ability." The KRG group had less deterioration in the FACIT-Fatigue Total score and a reduction in the perceived stress scale from baseline to week 16, but the differences were not significant. Neutropenia was more frequent with KRG (19 versus 10 percent), but the incidence of all adverse events was similar. The only potential side effect attributed to KRG was hypertensive crisis (defined as grade 3 hypertension  (<a class="graphic graphic_table graphicRef87347" href="/d/graphic/87347.html" rel="external">table 11</a>)), which developed in three patients receiving KRG compared with only one in the placebo group.</p><p></p><p class="bulletIndent1">One concern about recommending widespread use of ginseng as a treatment for CRF is the potential for drug interactions (especially with <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a>, monoamine oxidase inhibitors, calcium channel blockers, cholesterol-lowering agents, antiplatelet agents, thrombolytic agents, diuretics, hormonal agents, and some chemotherapy drugs) [<a href="#rid177">177,178</a>]. In vitro studies suggest that ginseng inhibits <em>CYP3A4</em>, and clinical studies suggest a potentially relevant interaction between ginseng and some antineoplastic agents that inhibit <em>CYP3A4</em>, such as <a class="drug drug_general" data-topicid="8961" href="/d/drug information/8961.html" rel="external">imatinib</a> [<a href="#rid179">179</a>], but not other <em>CYP3A4</em> inducers such as <a class="drug drug_general" data-topicid="8573" href="/d/drug information/8573.html" rel="external">irinotecan</a> and <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a> [<a href="#rid180">180,181</a>].</p><p></p><p class="bulletIndent1">An overview of herbal medicines and potential interactions of herbal medicines with chemotherapy agents is available elsewhere in UpToDate. (See  <a class="medical medical_review" href="/d/html/1392.html" rel="external">"Overview of herbal medicine and dietary supplements"</a> and  <a class="medical medical_review" href="/d/html/2831.html" rel="external">"Overview of complementary, alternative, and integrative medicine practices in oncology care, and potential risks and harm"</a>.)</p><p></p><p class="bulletIndent1">In addition, patient-oriented information about American and Asian ginseng is available through <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fmedlineplus.gov%2Fdruginfo%2Fnatural%2F967.html&amp;token=d5ngiCbB8xFYJWkFI1xcekh7CTTcVcbY3fVxLXEvc7R%2F1D22W2Xd3HUFwcxXTYTGsR%2BbwVaoXMHywGr8%2BzePnw%3D%3D&amp;TOPIC_ID=2813" target="_blank">MedlinePlus National Library of Medicine (NLM).</a> More comprehensive clinician-oriented information on specific interactions of ginseng with other medications is available using the <a class="external" href="/drug-interactions">drug interactions program</a> included with UpToDate. This program can be accessed from the UpToDate online search page or through the individual drug information topics in the section on Drug interactions.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Guarana</strong> – For most patients with CRF, we suggest not pursuing treatment with guarana.</p><p></p><p class="bulletIndent1">Guarana is a stimulant derived from an extract of seeds from a plant in the Amazo<em>n (Paullinia cupana</em>). In an early small double-blind, placebo-controlled crossover study of 75 breast cancer patients receiving chemotherapy, oral guarana at a dose of 100 mg daily significantly improved fatigue scores at the end of 21 days of treatment [<a href="#rid182">182</a>]. On the other hand, a second small trial failed to confirm benefit in patients with postradiotherapy fatigue [<a href="#rid183">183</a>].</p><p></p><p class="bulletIndent1">Benefit for guarana for treatment of CRF could also not be shown in a systematic review and meta-analysis of seven placebo-controlled trials of guarana that addressed the impact on fatigue in cancer patients (including the double-blind trial reported above); all studies had been conducted in Brazil [<a href="#rid184">184</a>]. The quantity of guarana extract varied between 15 and 100 mg daily, and intervention periods varied between 21 and 90 days. In the meta-analysis, which was restricted to three randomized trials conducted in women with breast cancer, guarana did not reduce CRF compared with placebo (mean difference in brief fatigue inventory -0.2, 95% CI -1.54 to +1.50); however, the quality of the evidence was very low. The most common adverse effects of treatment were tachycardia, insomnia, nausea, and anxiety, in both groups.</p><p></p><p class="bulletIndent3">Additional high-quality studies are needed to address the benefits of guarana for chronic CRF in breast cancer and in other types of cancer, and to evaluate long-term side effects and drug-drug interactions.</p><p></p><p class="headingAnchor" id="H1921524404"><span class="h4">Vitamins</span><span class="headingEndMark"> — </span>The evidence to date suggests that multivitamin supplementation is ineffective at reducing CRF [<a href="#rid139">139,185</a>]. However, the available trials vary greatly in quality; most are methodologically weak and at high risk of bias. Consequently, the evidence is inconclusive.</p><p class="headingAnchor" id="H3939696748"><span class="h4">Clinical practice guidelines</span><span class="headingEndMark"> — </span>Our recommendations for use of ginseng and guarana in patients with CRF are consistent with the year 2017 clinical practice guideline on the use of integrative therapies in patients during and after breast cancer treatment from the SIO [<a href="#rid144">144</a>], which was subsequently endorsed by ASCO [<a href="#rid145">145</a>]. The recommendation to consider a trial of ginseng for improving fatigue during treatment received a "C" grade (weak evidence of benefit) due primarily to a lack of multiple large trials. The use of guarana was not recommended for improving fatigue during treatment. There was insufficient evidence on vitamins to form a recommendation for or against.</p><p class="headingAnchor" id="H3065739917"><span class="h1">EXPERT GROUP RECOMMENDATIONS FOR CANCER SURVIVORS</span><span class="headingEndMark"> — </span>Specific guidelines for screening, assessment, and management of fatigue in adult survivors of cancer are available from the American Society of Clinical Oncology, and outlined in the table  (<a class="graphic graphic_table graphicRef94894" href="/d/graphic/94894.html" rel="external">table 12</a>) [<a href="#rid10">10</a>].</p><p>Guidelines are also available from the National Comprehensive Cancer Network that emphasize [<a href="#rid186">186</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Maintenance of adequate levels of physical activity with use of local resources to help patients to increase exercise, and referral to a physical therapist or exercise specialist for survivors at higher risk of injury (eg, those living with neuropathy, cardiomyopathy, or lymphedema).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Behavioral interventions such as cognitive behavioral therapy, psychoeducational therapy, and nutritional consultation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A trial of psychostimulants after ruling out other causes of fatigue and failure of other interventions.</p><p></p><p class="headingAnchor" id="H2083933"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/16250.html" rel="external">"Patient education: When your cancer treatment makes you tired (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H19"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Screening and assessment</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Cancer-related fatigue (CRF) is a common, distressing, and potentially treatable condition. The most important contributory factors are cancer and cancer treatment, anemia, pain (and its treatment), emotional distress, sleep disturbance, poor nutrition, and other comorbidities. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>All cancer patients should be screened for fatigue at the initial visit, at the end of treatment, as clinically indicated (at least annually) during the period of cancer survivorship, at the time that advanced disease is diagnosed, and at all chemotherapy visits. Specific recommendations for screening and assessment are provided separately. (See  <a class="medical medical_review" href="/d/html/2802.html" rel="external">"Cancer-related fatigue: Prevalence, screening, and clinical assessment"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General measures and control of contributory factors</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with mild fatigue (VAS score 1 to 3 on a scale of 1 to 10) that does not interfere with activities of daily living (ADLs) can be reassured and counseled as to coping strategies that conserve energy  (<a class="graphic graphic_table graphicRef73183" href="/d/graphic/73183.html" rel="external">table 5</a> and <a class="graphic graphic_table graphicRef53415" href="/d/graphic/53415.html" rel="external">table 6</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For individuals with moderate to severe fatigue, potentially treatable causes of or contributory factors to fatigue should be sought for and treated  (<a class="graphic graphic_table graphicRef98133" href="/d/graphic/98133.html" rel="external">table 1</a>). (See <a class="local">'General approach'</a> above and <a class="local">'Control of contributory factors'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients with insomnia or sleep disorders, specific measures to improve sleep hygiene should be suggested  (<a class="graphic graphic_table graphicRef50224" href="/d/graphic/50224.html" rel="external">table 4</a>). For most patients, we discourage the use of medications to aid sleep. (See <a class="local">'Sleep disturbance'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients with suspected opioid-induced sedation the dose should be titrated or the schedule/agent modified so as to alleviate pain without causing significant sedation. If needed, a trial of psychostimulants may help. (See <a class="local">'Patients receiving opioids'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients with a significant mood disorder, we suggest a therapeutic trial of an antidepressant (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). (See <a class="local">'Antidepressants'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For men with CRF with hypogonadism we suggest a therapeutic trial of <a class="drug drug_general" data-topicid="9981" href="/d/drug information/9981.html" rel="external">testosterone</a> supplementation (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). (See <a class="local">'Testosterone for hypogonadal men'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients receiving active cancer therapy</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patients with anemia</strong> <strong>–</strong> The underlying causes of anemia should be identified and treated if possible. If a potentially reversible cause cannot be identified, hemoglobin (Hb) levels can be raised with either erythropoiesis-stimulating agents (ESAs) or red blood cell (RBC) transfusions  (<a class="graphic graphic_table graphicRef78476" href="/d/graphic/78476.html" rel="external">table 3</a>). Specific recommendations are provided separately. (See  <a class="medical medical_review" href="/d/html/2799.html" rel="external">"Role of erythropoiesis-stimulating agents in the treatment of anemia in patients with cancer", section on 'Managing anemia in cancer patients'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patients without anemia</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For most patients, we encourage an individualized program of moderate aerobic exercise unless contraindicated (eg, by the presence of extensive lytic bone metastases, extensive cachexia, extreme thrombocytopenia, fever or active infection, or safety issues). (See <a class="local">'Exercise'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Additionally, some form of psychosocial and behavioral intervention is likely to be of benefit. Structured support groups may help some patients, while others may benefit from individual counseling for stress management, depression, and anxiety; relaxation training; or a comprehensive program that enhances coping skills. (See <a class="local">'Cognitive-behavioral interventions'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Mind-body practices such as yoga, acupuncture, Tai chi, or mindfulness-based approaches may also be of helpful, if patients are interested in these approaches and practitioners are available. (See <a class="local">'Mind and body practices'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients with severe fatigue (Brief Fatigue Inventory [BFI] question #3 &gt;7) in whom nonpharmacologic methods do not resolve fatigue we suggest a psychostimulant (eg, <a class="drug drug_general" data-topicid="9638" href="/d/drug information/9638.html" rel="external">methylphenidate</a>, <a class="drug drug_general" data-topicid="8667" href="/d/drug information/8667.html" rel="external">dexmethylphenidate</a>, or <a class="drug drug_general" data-topicid="10157" href="/d/drug information/10157.html" rel="external">modafinil</a>) rather than other agents (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). However, for those in the terminal phase of their illness, a trial of glucocorticoids is an appropriate alternative. (See <a class="local">'Psychostimulants and other wakefulness agents'</a> above and <a class="local">'Glucocorticoids'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>A trial of ginseng is a reasonable complementary option, as long as the patient is not receiving drugs that may interact unfavorably with ginseng, such as anticoagulants. For most patients, we do not offer guarana. (See <a class="local">'Ginseng and guarana'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cancer survivors</strong> – Our recommended approach to treatment of cancer survivors is consistent with guidelines from the American Society of Clinical Oncology  (<a class="graphic graphic_table graphicRef94894" href="/d/graphic/94894.html" rel="external">table 12</a>) and the National Comprehensive Cancer Network (see <a class="local">'Expert group recommendations for cancer survivors'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For most patients, we suggest an individualized program of moderate aerobic exercise (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). Walking programs are generally safe for most cancer survivors; patients can begin this type of program after consulting with their doctors, without any formal exercise testing (eg, a stress test). Patients at higher risk of injury (ie, those with neuropathy, cardiomyopathy, or other long-term effects of cancer therapy) should be referred to a physical therapist or exercise specialist prior to embarking on an exercise program. (See <a class="local">'Exercise'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If fatigue persists despite exercise, cognitive behavioral therapy and mind-body practices such as yoga, acupuncture, Tai chi, or mindfulness-based approaches may be of benefit, if patients are interested in these approaches and practitioners are available. (See <a class="local">'Mind and body practices'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For survivors with severe fatigue after completing cancer treatment (BFI question #3 &gt;7) that remains unresolved with nonpharmacologic treatments, and no other potentially treatable cause is identified, some clinicians would offer a therapeutic trial of a psychostimulant or other wakefulness agent. (See <a class="local">'Psychostimulants and other wakefulness agents'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Cella D, Peterman A, Passik S, et al. Progress toward guidelines for the management of fatigue. Oncology (Williston Park) 1998; 12:369.</a></li><li><a class="nounderline abstract_t">Glaus A, Crow R, Hammond S. A qualitative study to explore the concept of fatigue/tiredness in cancer patients and in healthy individuals. Support Care Cancer 1996; 4:82.</a></li><li><a class="nounderline abstract_t">Mock V, Dow KH, Meares CJ, et al. Effects of exercise on fatigue, physical functioning, and emotional distress during radiation therapy for breast cancer. Oncol Nurs Forum 1997; 24:991.</a></li><li><a class="nounderline abstract_t">Bloom JR, Fobair P, Gritz E, et al. Psychosocial outcomes of cancer: a comparative analysis of Hodgkin's disease and testicular cancer. J Clin Oncol 1993; 11:979.</a></li><li><a class="nounderline abstract_t">Dagnelie PC, Pijls-Johannesma MC, Lambin P, et al. Impact of fatigue on overall quality of life in lung and breast cancer patients selected for high-dose radiotherapy. Ann Oncol 2007; 18:940.</a></li><li><a class="nounderline abstract_t">Gupta D, Lis CG, Grutsch JF. The relationship between cancer-related fatigue and patient satisfaction with quality of life in cancer. J Pain Symptom Manage 2007; 34:40.</a></li><li><a class="nounderline abstract_t">Spelten ER, Verbeek JH, Uitterhoeve AL, et al. Cancer, fatigue and the return of patients to work-a prospective cohort study. Eur J Cancer 2003; 39:1562.</a></li><li><a class="nounderline abstract_t">Stone P, Richardson A, Ream E, et al. Cancer-related fatigue: inevitable, unimportant and untreatable? Results of a multi-centre patient survey. Cancer Fatigue Forum. Ann Oncol 2000; 11:971.</a></li><li><a class="nounderline abstract_t">Dy SM, Lorenz KA, Naeim A, et al. Evidence-based recommendations for cancer fatigue, anorexia, depression, and dyspnea. J Clin Oncol 2008; 26:3886.</a></li><li><a class="nounderline abstract_t">Bower JE, Bak K, Berger A, et al. Screening, assessment, and management of fatigue in adult survivors of cancer: an American Society of Clinical Oncology clinical practice guideline adaptation. J Clin Oncol 2014; 32:1840.</a></li><li class="breakAll">https://www.nccn.org/professionals/physician_gls/pdf/fatigue.pdf (Accessed on April 22, 2019).</li><li><a class="nounderline abstract_t">Basch E, Schrag D, Henson S, et al. Effect of Electronic Symptom Monitoring on Patient-Reported Outcomes Among Patients With Metastatic Cancer: A Randomized Clinical Trial. JAMA 2022; 327:2413.</a></li><li><a class="nounderline abstract_t">Howell D, Keller-Olaman S, Oliver TK, et al. A pan-Canadian practice guideline and algorithm: screening, assessment, and supportive care of adults with cancer-related fatigue. Curr Oncol 2013; 20:e233.</a></li><li><a class="nounderline abstract_t">Mitchell SA, Beck SL, Hood LE, et al. Putting evidence into practice: evidence-based interventions for fatigue during and following cancer and its treatment. Clin J Oncol Nurs 2007; 11:99.</a></li><li><a class="nounderline abstract_t">de Raaf PJ, de Klerk C, Timman R, et al. Systematic monitoring and treatment of physical symptoms to alleviate fatigue in patients with advanced cancer: a randomized controlled trial. J Clin Oncol 2013; 31:716.</a></li><li><a class="nounderline abstract_t">Littlewood TJ, Kallich JD, San Miguel J, et al. Efficacy of darbepoetin alfa in alleviating fatigue and the effect of fatigue on quality of life in anemic patients with lymphoproliferative malignancies. J Pain Symptom Manage 2006; 31:317.</a></li><li><a class="nounderline abstract_t">Rizzo JD, Somerfield MR, Hagerty KL, et al. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update. J Clin Oncol 2008; 26:132.</a></li><li><a class="nounderline abstract_t">Schmitz KH, Courneya KS, Matthews C, et al. American College of Sports Medicine roundtable on exercise guidelines for cancer survivors. Med Sci Sports Exerc 2010; 42:1409.</a></li><li><a class="nounderline abstract_t">Lucía A, Earnest C, Pérez M. Cancer-related fatigue: can exercise physiology assist oncologists? Lancet Oncol 2003; 4:616.</a></li><li><a class="nounderline abstract_t">Segal R, Evans W, Johnson D, et al. Structured exercise improves physical functioning in women with stages I and II breast cancer: results of a randomized controlled trial. J Clin Oncol 2001; 19:657.</a></li><li><a class="nounderline abstract_t">Dimeo F, Fetscher S, Lange W, et al. Effects of aerobic exercise on the physical performance and incidence of treatment-related complications after high-dose chemotherapy. Blood 1997; 90:3390.</a></li><li><a class="nounderline abstract_t">Windsor PM, Nicol KF, Potter J. A randomized, controlled trial of aerobic exercise for treatment-related fatigue in men receiving radical external beam radiotherapy for localized prostate carcinoma. Cancer 2004; 101:550.</a></li><li><a class="nounderline abstract_t">Thorsen L, Skovlund E, Strømme SB, et al. Effectiveness of physical activity on cardiorespiratory fitness and health-related quality of life in young and middle-aged cancer patients shortly after chemotherapy. J Clin Oncol 2005; 23:2378.</a></li><li><a class="nounderline abstract_t">Keogh JW, MacLeod RD. Body composition, physical fitness, functional performance, quality of life, and fatigue benefits of exercise for prostate cancer patients: a systematic review. J Pain Symptom Manage 2012; 43:96.</a></li><li><a class="nounderline abstract_t">Machado P, Morgado M, Raposo J, et al. Effectiveness of exercise training on cancer-related fatigue in colorectal cancer survivors: a systematic review and meta-analysis of randomized controlled trials. Support Care Cancer 2022; 30:5601.</a></li><li><a class="nounderline abstract_t">Cramer H, Lauche R, Klose P, et al. A systematic review and meta-analysis of exercise interventions for colorectal cancer patients. Eur J Cancer Care (Engl) 2014; 23:3.</a></li><li><a class="nounderline abstract_t">McGettigan M, Cardwell CR, Cantwell MM, Tully MA. Physical activity interventions for disease-related physical and mental health during and following treatment in people with non-advanced colorectal cancer. Cochrane Database Syst Rev 2020; 5:CD012864.</a></li><li><a class="nounderline abstract_t">Singh B, Hayes SC, Spence RR, et al. Exercise and colorectal cancer: a systematic review and meta-analysis of exercise safety, feasibility and effectiveness. Int J Behav Nutr Phys Act 2020; 17:122.</a></li><li><a class="nounderline abstract_t">Griffith K, Wenzel J, Shang J, et al. Impact of a walking intervention on cardiorespiratory fitness, self-reported physical function, and pain in patients undergoing treatment for solid tumors. Cancer 2009; 115:4874.</a></li><li><a class="nounderline abstract_t">Dimeo F, Schwartz S, Fietz T, et al. Effects of endurance training on the physical performance of patients with hematological malignancies during chemotherapy. Support Care Cancer 2003; 11:623.</a></li><li><a class="nounderline abstract_t">Dimeo FC, Stieglitz RD, Novelli-Fischer U, et al. Effects of physical activity on the fatigue and psychologic status of cancer patients during chemotherapy. Cancer 1999; 85:2273.</a></li><li><a class="nounderline abstract_t">Courneya KS, Mackey JR, Bell GJ, et al. Randomized controlled trial of exercise training in postmenopausal breast cancer survivors: cardiopulmonary and quality of life outcomes. J Clin Oncol 2003; 21:1660.</a></li><li><a class="nounderline abstract_t">Courneya KS, Sellar CM, Stevinson C, et al. Randomized controlled trial of the effects of aerobic exercise on physical functioning and quality of life in lymphoma patients. J Clin Oncol 2009; 27:4605.</a></li><li><a class="nounderline abstract_t">Segal RJ, Reid RD, Courneya KS, et al. Resistance exercise in men receiving androgen deprivation therapy for prostate cancer. J Clin Oncol 2003; 21:1653.</a></li><li><a class="nounderline abstract_t">Segal RJ, Reid RD, Courneya KS, et al. Randomized controlled trial of resistance or aerobic exercise in men receiving radiation therapy for prostate cancer. J Clin Oncol 2009; 27:344.</a></li><li><a class="nounderline abstract_t">Steindorf K, Schmidt ME, Klassen O, et al. Randomized, controlled trial of resistance training in breast cancer patients receiving adjuvant radiotherapy: results on cancer-related fatigue and quality of life. Ann Oncol 2014; 25:2237.</a></li><li><a class="nounderline abstract_t">Schmidt ME, Wiskemann J, Armbrust P, et al. Effects of resistance exercise on fatigue and quality of life in breast cancer patients undergoing adjuvant chemotherapy: A randomized controlled trial. Int J Cancer 2015; 137:471.</a></li><li><a class="nounderline abstract_t">Cantarero-Villanueva I, Fernández-Lao C, Cuesta-Vargas AI, et al. The effectiveness of a deep water aquatic exercise program in cancer-related fatigue in breast cancer survivors: a randomized controlled trial. Arch Phys Med Rehabil 2013; 94:221.</a></li><li><a class="nounderline abstract_t">Milne HM, Wallman KE, Gordon S, Courneya KS. Effects of a combined aerobic and resistance exercise program in breast cancer survivors: a randomized controlled trial. Breast Cancer Res Treat 2008; 108:279.</a></li><li><a class="nounderline abstract_t">Adamsen L, Quist M, Andersen C, et al. Effect of a multimodal high intensity exercise intervention in cancer patients undergoing chemotherapy: randomised controlled trial. BMJ 2009; 339:b3410.</a></li><li><a class="nounderline abstract_t">Oldervoll LM, Loge JH, Lydersen S, et al. Physical exercise for cancer patients with advanced disease: a randomized controlled trial. Oncologist 2011; 16:1649.</a></li><li><a class="nounderline abstract_t">Cheville AL, Kollasch J, Vandenberg J, et al. A home-based exercise program to improve function, fatigue, and sleep quality in patients with Stage IV lung and colorectal cancer: a randomized controlled trial. J Pain Symptom Manage 2013; 45:811.</a></li><li><a class="nounderline abstract_t">Schwartz AL, Mori M, Gao R, et al. Exercise reduces daily fatigue in women with breast cancer receiving chemotherapy. Med Sci Sports Exerc 2001; 33:718.</a></li><li><a class="nounderline abstract_t">Huizinga F, Westerink NL, Berendsen AJ, et al. Home-based Physical Activity to Alleviate Fatigue in Cancer Survivors: A Systematic Review and Meta-analysis. Med Sci Sports Exerc 2021; 53:2661.</a></li><li><a class="nounderline abstract_t">Ligibel JA, Bohlke K, May AM, et al. Exercise, Diet, and Weight Management During Cancer Treatment: ASCO Guideline. J Clin Oncol 2022; 40:2491.</a></li><li><a class="nounderline abstract_t">Hilfiker R, Meichtry A, Eicher M, et al. Exercise and other non-pharmaceutical interventions for cancer-related fatigue in patients during or after cancer treatment: a systematic review incorporating an indirect-comparisons meta-analysis. Br J Sports Med 2018; 52:651.</a></li><li><a class="nounderline abstract_t">Oberoi S, Robinson PD, Cataudella D, et al. Physical activity reduces fatigue in patients with cancer and hematopoietic stem cell transplant recipients: A systematic review and meta-analysis of randomized trials. Crit Rev Oncol Hematol 2018; 122:52.</a></li><li><a class="nounderline abstract_t">Knips L, Bergenthal N, Streckmann F, et al. Aerobic physical exercise for adult patients with haematological malignancies. Cochrane Database Syst Rev 2019; 1:CD009075.</a></li><li><a class="nounderline abstract_t">Ehlers DK, DuBois K, Salerno EA. The effects of exercise on cancer-related fatigue in breast cancer patients during primary treatment: a meta-analysis and systematic review. Expert Rev Anticancer Ther 2020; 20:865.</a></li><li><a class="nounderline abstract_t">Abo S, Denehy L, Ritchie D, et al. People With Hematological Malignancies Treated With Bone Marrow Transplantation Have Improved Function, Quality of Life, and Fatigue Following Exercise Intervention: A Systematic Review and Meta-Analysis. Phys Ther 2021; 101.</a></li><li><a class="nounderline abstract_t">Horgan S, O'Donovan A. The Impact of Exercise during Radiation Therapy for Prostate Cancer on Fatigue and Quality of Life: A Systematic Review and Meta-analysis. J Med Imaging Radiat Sci 2018; 49:207.</a></li><li><a class="nounderline abstract_t">Lund CM, Dolin TG, Mikkelsen MK, et al. Effect of Exercise on Physical Function and Psychological Well-being in Older Patients With Colorectal Cancer Receiving Chemotherapy-A Systematic Review. Clin Colorectal Cancer 2020; 19:e243.</a></li><li><a class="nounderline abstract_t">Singh B, Spence R, Steele ML, et al. Exercise for Individuals With Lung Cancer: A Systematic Review and Meta-Analysis of Adverse Events, Feasibility, and Effectiveness. Semin Oncol Nurs 2020; 36:151076.</a></li><li><a class="nounderline abstract_t">Kreutz C, Schmidt ME, Steindorf K. Effects of physical and mind-body exercise on sleep problems during and after breast cancer treatment: a systematic review and meta-analysis. Breast Cancer Res Treat 2019; 176:1.</a></li><li><a class="nounderline abstract_t">Vallance JK, Courneya KS, Plotnikoff RC, et al. Randomized controlled trial of the effects of print materials and step pedometers on physical activity and quality of life in breast cancer survivors. J Clin Oncol 2007; 25:2352.</a></li><li><a class="nounderline abstract_t">VAN Vulpen JK, Sweegers MG, Peeters PHM, et al. Moderators of Exercise Effects on Cancer-related Fatigue: A Meta-analysis of Individual Patient Data. Med Sci Sports Exerc 2020; 52:303.</a></li><li><a class="nounderline abstract_t">Fabi A, Bhargava R, Fatigoni S, et al. Cancer-related fatigue: ESMO Clinical Practice Guidelines for diagnosis and treatment. Ann Oncol 2020; 31:713.</a></li><li><a class="nounderline abstract_t">Barsevick AM, Dudley W, Beck S, et al. A randomized clinical trial of energy conservation for patients with cancer-related fatigue. Cancer 2004; 100:1302.</a></li><li><a class="nounderline abstract_t">Ream E, Richardson A, Alexander-Dann C. Supportive intervention for fatigue in patients undergoing chemotherapy: a randomized controlled trial. J Pain Symptom Manage 2006; 31:148.</a></li><li><a class="nounderline abstract_t">Armes J, Chalder T, Addington-Hall J, et al. A randomized controlled trial to evaluate the effectiveness of a brief, behaviorally oriented intervention for cancer-related fatigue. Cancer 2007; 110:1385.</a></li><li><a class="nounderline abstract_t">Yates P, Aranda S, Hargraves M, et al. Randomized controlled trial of an educational intervention for managing fatigue in women receiving adjuvant chemotherapy for early-stage breast cancer. J Clin Oncol 2005; 23:6027.</a></li><li><a class="nounderline abstract_t">Lotfi-Jam K, Carey M, Jefford M, et al. Nonpharmacologic strategies for managing common chemotherapy adverse effects: a systematic review. J Clin Oncol 2008; 26:5618.</a></li><li><a class="nounderline abstract_t">Goedendorp MM, Gielissen MF, Verhagen CA, Bleijenberg G. Psychosocial interventions for reducing fatigue during cancer treatment in adults. Cochrane Database Syst Rev 2009; :CD006953.</a></li><li><a class="nounderline abstract_t">Kwekkeboom KL, Abbott-Anderson K, Cherwin C, et al. Pilot randomized controlled trial of a patient-controlled cognitive-behavioral intervention for the pain, fatigue, and sleep disturbance symptom cluster in cancer. J Pain Symptom Manage 2012; 44:810.</a></li><li><a class="nounderline abstract_t">Montgomery GH, David D, Kangas M, et al. Randomized controlled trial of a cognitive-behavioral therapy plus hypnosis intervention to control fatigue in patients undergoing radiotherapy for breast cancer. J Clin Oncol 2014; 32:557.</a></li><li><a class="nounderline abstract_t">Poort H, Peters MEWJ, van der Graaf WTA, et al. Cognitive behavioral therapy or graded exercise therapy compared with usual care for severe fatigue in patients with advanced cancer during treatment: a randomized controlled trial. Ann Oncol 2020; 31:115.</a></li><li><a class="nounderline abstract_t">Gielissen MF, Verhagen CA, Bleijenberg G. Cognitive behaviour therapy for fatigued cancer survivors: long-term follow-up. Br J Cancer 2007; 97:612.</a></li><li><a class="nounderline abstract_t">Poort H, Peters M, Bleijenberg G, et al. Psychosocial interventions for fatigue during cancer treatment with palliative intent. Cochrane Database Syst Rev 2017; 7:CD012030.</a></li><li><a class="nounderline abstract_t">Brown P, Clark MM, Atherton P, et al. Will improvement in quality of life (QOL) impact fatigue in patients receiving radiation therapy for advanced cancer? Am J Clin Oncol 2006; 29:52.</a></li><li><a class="nounderline abstract_t">Rummans TA, Clark MM, Sloan JA, et al. Impacting quality of life for patients with advanced cancer with a structured multidisciplinary intervention: a randomized controlled trial. J Clin Oncol 2006; 24:635.</a></li><li><a class="nounderline abstract_t">Duijts SF, Faber MM, Oldenburg HS, et al. Effectiveness of behavioral techniques and physical exercise on psychosocial functioning and health-related quality of life in breast cancer patients and survivors--a meta-analysis. Psychooncology 2011; 20:115.</a></li><li><a class="nounderline abstract_t">van der Lee ML, Garssen B. Mindfulness-based cognitive therapy reduces chronic cancer-related fatigue: a treatment study. Psychooncology 2012; 21:264.</a></li><li><a class="nounderline abstract_t">Jacobsen PB, Donovan KA, Vadaparampil ST, Small BJ. Systematic review and meta-analysis of psychological and activity-based interventions for cancer-related fatigue. Health Psychol 2007; 26:660.</a></li><li><a class="nounderline abstract_t">Kangas M, Bovbjerg DH, Montgomery GH. Cancer-related fatigue: a systematic and meta-analytic review of non-pharmacological therapies for cancer patients. Psychol Bull 2008; 134:700.</a></li><li><a class="nounderline abstract_t">Given C, Given B, Rahbar M, et al. Effect of a cognitive behavioral intervention on reducing symptom severity during chemotherapy. J Clin Oncol 2004; 22:507.</a></li><li><a class="nounderline abstract_t">Barsevick AM, Whitmer K, Sweeney C, Nail LM. A pilot study examining energy conservation for cancer treatment-related fatigue. Cancer Nurs 2002; 25:333.</a></li><li><a class="nounderline abstract_t">Graydon JE, Bubela N, Irvine D, Vincent L. Fatigue-reducing strategies used by patients receiving treatment for cancer. Cancer Nurs 1995; 18:23.</a></li><li><a class="nounderline abstract_t">Richardson A, Ream EK. Self-care behaviours initiated by chemotherapy patients in response to fatigue. Int J Nurs Stud 1997; 34:35.</a></li><li><a class="nounderline abstract_t">Schneider SM, Prince-Paul M, Allen MJ, et al. Virtual reality as a distraction intervention for women receiving chemotherapy. Oncol Nurs Forum 2004; 31:81.</a></li><li><a class="nounderline abstract_t">Weis J. Support groups for cancer patients. Support Care Cancer 2003; 11:763.</a></li><li><a class="nounderline abstract_t">Helgeson VS, Cohen S, Schulz R, Yasko J. Group support interventions for women with breast cancer: who benefits from what? Health Psychol 2000; 19:107.</a></li><li><a class="nounderline abstract_t">Forester B, Kornfeld DS, Fleiss JL, Thompson S. Group psychotherapy during radiotherapy: effects on emotional and physical distress. Am J Psychiatry 1993; 150:1700.</a></li><li><a class="nounderline abstract_t">Boesen EH, Ross L, Frederiksen K, et al. Psychoeducational intervention for patients with cutaneous malignant melanoma: a replication study. J Clin Oncol 2005; 23:1270.</a></li><li><a class="nounderline abstract_t">Forester B, Kornfeld DS, Fleiss JL. Psychotherapy during radiotherapy: effects on emotional and physical distress. Am J Psychiatry 1985; 142:22.</a></li><li><a class="nounderline abstract_t">Given B, Given CW, McCorkle R, et al. Pain and fatigue management: results of a nursing randomized clinical trial. Oncol Nurs Forum 2002; 29:949.</a></li><li><a class="nounderline abstract_t">Trijsburg RW, van Knippenberg FC, Rijpma SE. Effects of psychological treatment on cancer patients: a critical review. Psychosom Med 1992; 54:489.</a></li><li><a class="nounderline abstract_t">Jacobsen PB, Meade CD, Stein KD, et al. Efficacy and costs of two forms of stress management training for cancer patients undergoing chemotherapy. J Clin Oncol 2002; 20:2851.</a></li><li><a class="nounderline abstract_t">Decker TW, Cline-Elsen J, Gallagher M. Relaxation therapy as an adjunct in radiation oncology. J Clin Psychol 1992; 48:388.</a></li><li><a class="nounderline abstract_t">Carlson LE, Speca M, Patel KD, Goodey E. Mindfulness-based stress reduction in relation to quality of life, mood, symptoms of stress and levels of cortisol, dehydroepiandrosterone sulfate (DHEAS) and melatonin in breast and prostate cancer outpatients. Psychoneuroendocrinology 2004; 29:448.</a></li><li><a class="nounderline abstract_t">Luebbert K, Dahme B, Hasenbring M. The effectiveness of relaxation training in reducing treatment-related symptoms and improving emotional adjustment in acute non-surgical cancer treatment: a meta-analytical review. Psychooncology 2001; 10:490.</a></li><li><a class="nounderline abstract_t">Gaston-Johansson F, Fall-Dickson JM, Nanda J, et al. The effectiveness of the comprehensive coping strategy program on clinical outcomes in breast cancer autologous bone marrow transplantation. Cancer Nurs 2000; 23:277.</a></li><li><a class="nounderline abstract_t">Gielissen MF, Verhagen S, Witjes F, Bleijenberg G. Effects of cognitive behavior therapy in severely fatigued disease-free cancer patients compared with patients waiting for cognitive behavior therapy: a randomized controlled trial. J Clin Oncol 2006; 24:4882.</a></li><li><a class="nounderline abstract_t">Stanton AL, Ganz PA, Kwan L, et al. Outcomes from the Moving Beyond Cancer psychoeducational, randomized, controlled trial with breast cancer patients. J Clin Oncol 2005; 23:6009.</a></li><li><a class="nounderline abstract_t">Yun YH, Lee KS, Kim YW, et al. Web-based tailored education program for disease-free cancer survivors with cancer-related fatigue: a randomized controlled trial. J Clin Oncol 2012; 30:1296.</a></li><li><a class="nounderline abstract_t">Clark MM, Bostwick JM, Rummans TA. Group and individual treatment strategies for distress in cancer patients. Mayo Clin Proc 2003; 78:1538.</a></li><li><a class="nounderline abstract_t">Lengacher CA, Reich RR, Post-White J, et al. Mindfulness based stress reduction in post-treatment breast cancer patients: an examination of symptoms and symptom clusters. J Behav Med 2012; 35:86.</a></li><li><a class="nounderline abstract_t">Hoffman CJ, Ersser SJ, Hopkinson JB, et al. Effectiveness of mindfulness-based stress reduction in mood, breast- and endocrine-related quality of life, and well-being in stage 0 to III breast cancer: a randomized, controlled trial. J Clin Oncol 2012; 30:1335.</a></li><li><a class="nounderline abstract_t">Johns SA, Brown LF, Beck-Coon K, et al. Randomized controlled pilot trial of mindfulness-based stress reduction compared to psychoeducational support for persistently fatigued breast and colorectal cancer survivors. Support Care Cancer 2016; 24:4085.</a></li><li><a class="nounderline abstract_t">Bower JE, Crosswell AD, Stanton AL, et al. Mindfulness meditation for younger breast cancer survivors: a randomized controlled trial. Cancer 2015; 121:1231.</a></li><li><a class="nounderline abstract_t">Suh HW, Jeong HY, Hong S, et al. The mindfulness-based stress reduction program for improving sleep quality in cancer survivors: A systematic review and meta-analysis. Complement Ther Med 2021; 57:102667.</a></li><li><a class="nounderline abstract_t">Xie C, Dong B, Wang L, et al. Mindfulness-based stress reduction can alleviate cancer- related fatigue: A meta-analysis. J Psychosom Res 2020; 130:109916.</a></li><li><a class="nounderline abstract_t">Bower JE, Garet D, Sternlieb B, et al. Yoga for persistent fatigue in breast cancer survivors: a randomized controlled trial. Cancer 2012; 118:3766.</a></li><li><a class="nounderline abstract_t">Mustian KM, Sprod LK, Janelsins M, et al. Multicenter, randomized controlled trial of yoga for sleep quality among cancer survivors. J Clin Oncol 2013; 31:3233.</a></li><li><a class="nounderline abstract_t">Kiecolt-Glaser JK, Bennett JM, Andridge R, et al. Yoga's impact on inflammation, mood, and fatigue in breast cancer survivors: a randomized controlled trial. J Clin Oncol 2014; 32:1040.</a></li><li><a class="nounderline abstract_t">Chandwani KD, Perkins G, Nagendra HR, et al. Randomized, controlled trial of yoga in women with breast cancer undergoing radiotherapy. J Clin Oncol 2014; 32:1058.</a></li><li><a class="nounderline abstract_t">Banasik J, Williams H, Haberman M, et al. Effect of Iyengar yoga practice on fatigue and diurnal salivary cortisol concentration in breast cancer survivors. J Am Acad Nurse Pract 2011; 23:135.</a></li><li><a class="nounderline abstract_t">Zetzl T, Renner A, Pittig A, et al. Yoga effectively reduces fatigue and symptoms of depression in patients with different types of cancer. Support Care Cancer 2021; 29:2973.</a></li><li><a class="nounderline abstract_t">Cramer H, Rabsilber S, Lauche R, et al. Yoga and meditation for menopausal symptoms in breast cancer survivors-A randomized controlled trial. Cancer 2015; 121:2175.</a></li><li><a class="nounderline abstract_t">Littman AJ, Bertram LC, Ceballos R, et al. Randomized controlled pilot trial of yoga in overweight and obese breast cancer survivors: effects on quality of life and anthropometric measures. Support Care Cancer 2012; 20:267.</a></li><li><a class="nounderline abstract_t">Danhauer SC, Mihalko SL, Russell GB, et al. Restorative yoga for women with breast cancer: findings from a randomized pilot study. Psychooncology 2009; 18:360.</a></li><li><a class="nounderline abstract_t">Chandwani KD, Thornton B, Perkins GH, et al. Yoga improves quality of life and benefit finding in women undergoing radiotherapy for breast cancer. J Soc Integr Oncol 2010; 8:43.</a></li><li><a class="nounderline abstract_t">Jong MC, Boers I, Schouten van der Velden AP, et al. A Randomized Study of Yoga for Fatigue and Quality of Life in Women with Breast Cancer Undergoing (Neo) Adjuvant Chemotherapy. J Altern Complement Med 2018; 24:942.</a></li><li><a class="nounderline abstract_t">Lin PJ, Kleckner IR, Loh KP, et al. Influence of Yoga on Cancer-Related Fatigue and on Mediational Relationships Between Changes in Sleep and Cancer-Related Fatigue: A Nationwide, Multicenter Randomized Controlled Trial of Yoga in Cancer Survivors. Integr Cancer Ther 2019; 18:1534735419855134.</a></li><li><a class="nounderline abstract_t">Dong B, Xie C, Jing X, et al. Yoga has a solid effect on cancer-related fatigue in patients with breast cancer: a meta-analysis. Breast Cancer Res Treat 2019; 177:5.</a></li><li><a class="nounderline abstract_t">Deng G, Chan Y, Sjoberg D, et al. Acupuncture for the treatment of post-chemotherapy chronic fatigue: a randomized, blinded, sham-controlled trial. Support Care Cancer 2013; 21:1735.</a></li><li><a class="nounderline abstract_t">Vickers AJ, Straus DJ, Fearon B, Cassileth BR. Acupuncture for postchemotherapy fatigue: a phase II study. J Clin Oncol 2004; 22:1731.</a></li><li><a class="nounderline abstract_t">Molassiotis A, Sylt P, Diggins H. The management of cancer-related fatigue after chemotherapy with acupuncture and acupressure: a randomised controlled trial. Complement Ther Med 2007; 15:228.</a></li><li><a class="nounderline abstract_t">Molassiotis A, Bardy J, Finnegan-John J, et al. Acupuncture for cancer-related fatigue in patients with breast cancer: a pragmatic randomized controlled trial. J Clin Oncol 2012; 30:4470.</a></li><li><a class="nounderline abstract_t">Johnston MF, Hays RD, Subramanian SK, et al. Patient education integrated with acupuncture for relief of cancer-related fatigue randomized controlled feasibility study. BMC Complement Altern Med 2011; 11:49.</a></li><li><a class="nounderline abstract_t">Mao JJ, Farrar JT, Bruner D, et al. Electroacupuncture for fatigue, sleep, and psychological distress in breast cancer patients with aromatase inhibitor-related arthralgia: a randomized trial. Cancer 2014; 120:3744.</a></li><li><a class="nounderline abstract_t">Smith C, Carmady B, Thornton C, et al. The effect of acupuncture on post-cancer fatigue and well-being for women recovering from breast cancer: a pilot randomised controlled trial. Acupunct Med 2013; 31:9.</a></li><li><a class="nounderline abstract_t">Lim JT, Wong ET, Aung SK. Is there a role for acupuncture in the symptom management of patients receiving palliative care for cancer? A pilot study of 20 patients comparing acupuncture with nurse-led supportive care. Acupunct Med 2011; 29:173.</a></li><li><a class="nounderline abstract_t">Balk J, Day R, Rosenzweig M, Beriwal S. Pilot, randomized, modified, double-blind, placebo-controlled trial of acupuncture for cancer-related fatigue. J Soc Integr Oncol 2009; 7:4.</a></li><li><a class="nounderline abstract_t">Molassiotis A, Bardy J, Finnegan-John J, et al. A randomized, controlled trial of acupuncture self-needling as maintenance therapy for cancer-related fatigue after therapist-delivered acupuncture. Ann Oncol 2013; 24:1645.</a></li><li><a class="nounderline abstract_t">Azad A, John T. Do randomized acupuncture studies in patients with cancer need a sham acupuncture control arm? J Clin Oncol 2013; 31:2057.</a></li><li><a class="nounderline abstract_t">Zhang Y, Lin L, Li H, et al. Effects of acupuncture on cancer-related fatigue: a meta-analysis. Support Care Cancer 2018; 26:415.</a></li><li><a class="nounderline abstract_t">Mendoza ME, Capafons A, Gralow JR, et al. Randomized controlled trial of the Valencia model of waking hypnosis plus CBT for pain, fatigue, and sleep management in patients with cancer and cancer survivors. Psychooncology 2017; 26:1832.</a></li><li><a class="nounderline abstract_t">Montgomery GH, Kangas M, David D, et al. Fatigue during breast cancer radiotherapy: an initial randomized study of cognitive-behavioral therapy plus hypnosis. Health Psychol 2009; 28:317.</a></li><li><a class="nounderline abstract_t">Cramer H, Lauche R, Paul A, et al. Hypnosis in breast cancer care: a systematic review of randomized controlled trials. Integr Cancer Ther 2015; 14:5.</a></li><li><a class="nounderline abstract_t">Grégoire C, Nicolas H, Bragard I, et al. Efficacy of a hypnosis-based intervention to improve well-being during cancer: a comparison between prostate and breast cancer patients. BMC Cancer 2018; 18:677.</a></li><li><a class="nounderline abstract_t">Schnur JB, David D, Kangas M, et al. A randomized trial of a cognitive-behavioral therapy and hypnosis intervention on positive and negative affect during breast cancer radiotherapy. J Clin Psychol 2009; 65:443.</a></li><li><a class="nounderline abstract_t">Wayne PM, Lee MS, Novakowski J, et al. Tai Chi and Qigong for cancer-related symptoms and quality of life: a systematic review and meta-analysis. J Cancer Surviv 2018; 12:256.</a></li><li><a class="nounderline abstract_t">Larkey LK, Roe DJ, Weihs KL, et al. Randomized controlled trial of Qigong/Tai Chi Easy on cancer-related fatigue in breast cancer survivors. Ann Behav Med 2015; 49:165.</a></li><li><a class="nounderline abstract_t">Zhang LL, Wang SZ, Chen HL, Yuan AZ. Tai Chi Exercise for Cancer-Related Fatigue in Patients With Lung Cancer Undergoing Chemotherapy: A Randomized Controlled Trial. J Pain Symptom Manage 2016; 51:504.</a></li><li><a class="nounderline abstract_t">Zhou W, Wan YH, Chen Q, et al. Effects of Tai Chi Exercise on Cancer-Related Fatigue in Patients With Nasopharyngeal Carcinoma Undergoing Chemoradiotherapy: A Randomized Controlled Trial. J Pain Symptom Manage 2018; 55:737.</a></li><li><a class="nounderline abstract_t">Lu Y, Qu HQ, Chen FY, et al. Effect of Baduanjin Qigong Exercise on Cancer-Related Fatigue in Patients with Colorectal Cancer Undergoing Chemotherapy: A Randomized Controlled Trial. Oncol Res Treat 2019; 42:431.</a></li><li><a class="nounderline abstract_t">Irwin MR, Olmstead R, Carrillo C, et al. Tai Chi Chih Compared With Cognitive Behavioral Therapy for the Treatment of Insomnia in Survivors of Breast Cancer: A Randomized, Partially Blinded, Noninferiority Trial. J Clin Oncol 2017; 35:2656.</a></li><li><a class="nounderline abstract_t">Song S, Yu J, Ruan Y, et al. Ameliorative effects of Tai Chi on cancer-related fatigue: a meta-analysis of randomized controlled trials. Support Care Cancer 2018; 26:2091.</a></li><li><a class="nounderline abstract_t">Finnegan-John J, Molassiotis A, Richardson A, Ream E. A systematic review of complementary and alternative medicine interventions for the management of cancer-related fatigue. Integr Cancer Ther 2013; 12:276.</a></li><li><a class="nounderline abstract_t">Alizadeh J, Yeganeh MR, Pouralizadeh M, et al. The effect of massage therapy on fatigue after chemotherapy in gastrointestinal cancer patients. Support Care Cancer 2021; 29:7307.</a></li><li><a class="nounderline abstract_t">Qi Y, Lin L, Dong B, et al. Music interventions can alleviate cancer-related fatigue: a metaanalysis. Support Care Cancer 2021; 29:3461.</a></li><li><a class="nounderline abstract_t">Alcântara-Silva TR, de Freitas-Junior R, Freitas NMA, et al. Music Therapy Reduces Radiotherapy-Induced Fatigue in Patients With Breast or Gynecological Cancer: A Randomized Trial. Integr Cancer Ther 2018; 17:628.</a></li><li><a class="nounderline abstract_t">Sezgin MG, Bektas H. The effect of music therapy interventions on fatigue in patients with hematological cancers: a systematic review and meta-analysis of randomized controlled trials. Support Care Cancer 2022; 30:8733.</a></li><li><a class="nounderline abstract_t">Greenlee H, DuPont-Reyes MJ, Balneaves LG, et al. Clinical practice guidelines on the evidence-based use of integrative therapies during and after breast cancer treatment. CA Cancer J Clin 2017; 67:194.</a></li><li><a class="nounderline abstract_t">Lyman GH, Greenlee H, Bohlke K, et al. Integrative Therapies During and After Breast Cancer Treatment: ASCO Endorsement of the SIO Clinical Practice Guideline. J Clin Oncol 2018; 36:2647.</a></li><li><a class="nounderline abstract_t">Bruera E, Valero V, Driver L, et al. Patient-controlled methylphenidate for cancer fatigue: a double-blind, randomized, placebo-controlled trial. J Clin Oncol 2006; 24:2073.</a></li><li class="breakAll">Yennu S, et al. Open-labeled placebo for the treatment of cancer-related-fatigue in patients with advanced cancer: Results of a randomized controlled trial (abstract). J Clin Oncol 40, 2022 (suppl 16; abstr 12006). Abstraact available online at https://meetings.asco.org/2022-asco-annual-meeting/14422?presentation=209352#209352 (Accessed on July 05, 2022).</li><li><a class="nounderline abstract_t">Minton O, Richardson A, Sharpe M, et al. Drug therapy for the management of cancer-related fatigue. Cochrane Database Syst Rev 2010; :CD006704.</a></li><li><a class="nounderline abstract_t">Lower EE, Fleishman S, Cooper A, et al. Efficacy of dexmethylphenidate for the treatment of fatigue after cancer chemotherapy: a randomized clinical trial. J Pain Symptom Manage 2009; 38:650.</a></li><li><a class="nounderline abstract_t">Auret KA, Schug SA, Bremner AP, Bulsara M. A randomized, double-blind, placebo-controlled trial assessing the impact of dexamphetamine on fatigue in patients with advanced cancer. J Pain Symptom Manage 2009; 37:613.</a></li><li><a class="nounderline abstract_t">Mar Fan HG, Clemons M, Xu W, et al. A randomised, placebo-controlled, double-blind trial of the effects of d-methylphenidate on fatigue and cognitive dysfunction in women undergoing adjuvant chemotherapy for breast cancer. Support Care Cancer 2008; 16:577.</a></li><li><a class="nounderline abstract_t">Butler JM Jr, Case LD, Atkins J, et al. A phase III, double-blind, placebo-controlled prospective randomized clinical trial of d-threo-methylphenidate HCl in brain tumor patients receiving radiation therapy. Int J Radiat Oncol Biol Phys 2007; 69:1496.</a></li><li><a class="nounderline abstract_t">Moraska AR, Sood A, Dakhil SR, et al. Phase III, randomized, double-blind, placebo-controlled study of long-acting methylphenidate for cancer-related fatigue: North Central Cancer Treatment Group NCCTG-N05C7 trial. J Clin Oncol 2010; 28:3673.</a></li><li><a class="nounderline abstract_t">Bruera E, Yennurajalingam S, Palmer JL, et al. Methylphenidate and/or a nursing telephone intervention for fatigue in patients with advanced cancer: a randomized, placebo-controlled, phase II trial. J Clin Oncol 2013; 31:2421.</a></li><li><a class="nounderline abstract_t">Kerr CW, Drake J, Milch RA, et al. Effects of methylphenidate on fatigue and depression: a randomized, double-blind, placebo-controlled trial. J Pain Symptom Manage 2012; 43:68.</a></li><li><a class="nounderline abstract_t">Escalante CP, Meyers C, Reuben JM, et al. A randomized, double-blind, 2-period, placebo-controlled crossover trial of a sustained-release methylphenidate in the treatment of fatigue in cancer patients. Cancer J 2014; 20:8.</a></li><li><a class="nounderline abstract_t">Stone PC. Methylphenidate in the management of cancer-related fatigue. J Clin Oncol 2013; 31:2372.</a></li><li><a class="nounderline abstract_t">Wilwerding MB, Loprinzi CL, Mailliard JA, et al. A randomized, crossover evaluation of methylphenidate in cancer patients receiving strong narcotics. Support Care Cancer 1995; 3:135.</a></li><li><a class="nounderline abstract_t">Spathis A, Dhillan R, Booden D, et al. Modafinil for the treatment of fatigue in lung cancer: a pilot study. Palliat Med 2009; 23:325.</a></li><li><a class="nounderline abstract_t">Blackhall L, Petroni G, Shu J, et al. A pilot study evaluating the safety and efficacy of modafinal for cancer-related fatigue. J Palliat Med 2009; 12:433.</a></li><li><a class="nounderline abstract_t">Jean-Pierre P, Morrow GR, Roscoe JA, et al. A phase 3 randomized, placebo-controlled, double-blind, clinical trial of the effect of modafinil on cancer-related fatigue among 631 patients receiving chemotherapy: a University of Rochester Cancer Center Community Clinical Oncology Program Research base study. Cancer 2010; 116:3513.</a></li><li><a class="nounderline abstract_t">Spathis A, Fife K, Blackhall F, et al. Modafinil for the treatment of fatigue in lung cancer: results of a placebo-controlled, double-blind, randomized trial. J Clin Oncol 2014; 32:1882.</a></li><li><a class="nounderline abstract_t">Del Fabbro E, Hui D, Nooruddin ZI, et al. Associations among hypogonadism, C-reactive protein, symptom burden, and survival in male cancer patients with cachexia: a preliminary report. J Pain Symptom Manage 2010; 39:1016.</a></li><li><a class="nounderline abstract_t">Gagnon B, Murphy J, Jelowicki M, Morris DV. The effect of severe androgen deficiency on physical function in male patients with cancer. J Pain Symptom Manage 2013; 45:892.</a></li><li><a class="nounderline abstract_t">Del Fabbro E, Garcia JM, Dev R, et al. Testosterone replacement for fatigue in hypogonadal ambulatory males with advanced cancer: a preliminary double-blind placebo-controlled trial. Support Care Cancer 2013; 21:2599.</a></li><li><a class="nounderline abstract_t">Tsimafeyeu I, Tishova Y, Zukov R, et al. Testosterone for Managing Treatment-related Fatigue in Patients With Metastatic Renal Cell Carcinoma: A Phase 2 Randomized Study FARETES. Am J Clin Oncol 2021; 44:137.</a></li><li><a class="nounderline abstract_t">Morrow GR, Hickok JT, Roscoe JA, et al. Differential effects of paroxetine on fatigue and depression: a randomized, double-blind trial from the University of Rochester Cancer Center Community Clinical Oncology Program. J Clin Oncol 2003; 21:4635.</a></li><li><a class="nounderline abstract_t">Stockler MR, O'Connell R, Nowak AK, et al. Effect of sertraline on symptoms and survival in patients with advanced cancer, but without major depression: a placebo-controlled double-blind randomised trial. Lancet Oncol 2007; 8:603.</a></li><li><a class="nounderline abstract_t">Palesh OG, Mustian KM, Peppone LJ, et al. Impact of paroxetine on sleep problems in 426 cancer patients receiving chemotherapy: a trial from the University of Rochester Cancer Center Community Clinical Oncology Program. Sleep Med 2012; 13:1184.</a></li><li><a class="nounderline abstract_t">Bruera E, Roca E, Cedaro L, et al. Action of oral methylprednisolone in terminal cancer patients: a prospective randomized double-blind study. Cancer Treat Rep 1985; 69:751.</a></li><li><a class="nounderline abstract_t">Yennurajalingam S, Frisbee-Hume S, Palmer JL, et al. Reduction of cancer-related fatigue with dexamethasone: a double-blind, randomized, placebo-controlled trial in patients with advanced cancer. J Clin Oncol 2013; 31:3076.</a></li><li><a class="nounderline abstract_t">Sandford A, Haywood A, Rickett K, et al. Corticosteroids for the management of cancer-related fatigue in adults with advanced cancer. Cochrane Database Syst Rev 2023; 1:CD013782.</a></li><li><a class="nounderline abstract_t">Matsuo N, Morita T, Matsuda Y, et al. Predictors of Responses to Corticosteroids for Cancer-Related Fatigue in Advanced Cancer Patients: A Multicenter, Prospective, Observational Study. J Pain Symptom Manage 2016; 52:64.</a></li><li><a class="nounderline abstract_t">Barton DL, Soori GS, Bauer BA, et al. Pilot study of Panax quinquefolius (American ginseng) to improve cancer-related fatigue: a randomized, double-blind, dose-finding evaluation: NCCTG trial N03CA. Support Care Cancer 2010; 18:179.</a></li><li><a class="nounderline abstract_t">Barton DL, Liu H, Dakhil SR, et al. Wisconsin Ginseng (Panax quinquefolius) to improve cancer-related fatigue: a randomized, double-blind trial, N07C2. J Natl Cancer Inst 2013; 105:1230.</a></li><li><a class="nounderline abstract_t">Kim JW, Han SW, Cho JY, et al. Korean red ginseng for cancer-related fatigue in colorectal cancer patients with chemotherapy: A randomised phase III trial. Eur J Cancer 2020; 130:51.</a></li><li><a class="nounderline abstract_t">Posadzki P, Watson L, Ernst E. Herb-drug interactions: an overview of systematic reviews. Br J Clin Pharmacol 2013; 75:603.</a></li><li><a class="nounderline abstract_t">Chen XW, Sneed KB, Pan SY, et al. Herb-drug interactions and mechanistic and clinical considerations. Curr Drug Metab 2012; 13:640.</a></li><li><a class="nounderline abstract_t">Bilgi N, Bell K, Ananthakrishnan AN, Atallah E. Imatinib and Panax ginseng: a potential interaction resulting in liver toxicity. Ann Pharmacother 2010; 44:926.</a></li><li><a class="nounderline abstract_t">Izzo AA, Ernst E. Interactions between herbal medicines and prescribed drugs: an updated systematic review. Drugs 2009; 69:1777.</a></li><li><a class="nounderline abstract_t">Goey AK, Mooiman KD, Beijnen JH, et al. Relevance of in vitro and clinical data for predicting CYP3A4-mediated herb-drug interactions in cancer patients. Cancer Treat Rev 2013; 39:773.</a></li><li><a class="nounderline abstract_t">de Oliveira Campos MP, Riechelmann R, Martins LC, et al. Guarana (Paullinia cupana) improves fatigue in breast cancer patients undergoing systemic chemotherapy. J Altern Complement Med 2011; 17:505.</a></li><li><a class="nounderline abstract_t">da Costa Miranda V, Trufelli DC, Santos J, et al. Effectiveness of guaraná (Paullinia cupana) for postradiation fatigue and depression: results of a pilot double-blind randomized study. J Altern Complement Med 2009; 15:431.</a></li><li><a class="nounderline abstract_t">de Araujo DP, Pereira PTVT, Fontes AJC, et al. The use of guarana (Paullinia cupana) as a dietary supplement for fatigue in cancer patients: a systematic review with a meta-analysis. Support Care Cancer 2021; 29:7171.</a></li><li><a class="nounderline abstract_t">de Souza Fêde AB, Bensi CG, Trufelli DC, et al. Multivitamins do not improve radiation therapy-related fatigue: results of a double-blind randomized crossover trial. Am J Clin Oncol 2007; 30:432.</a></li><li class="breakAll">NCCN guidelines for supportive care in cancer patients available online at https://www.nccn.org/guidelines/ (Accessed on November 01, 2022).</li></ol></div><div id="topicVersionRevision">Topic 2813 Version 74.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10028520" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Progress toward guidelines for the management of fatigue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8673356" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : A qualitative study to explore the concept of fatigue/tiredness in cancer patients and in healthy individuals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9243585" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Effects of exercise on fatigue, physical functioning, and emotional distress during radiation therapy for breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8487061" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Psychosocial outcomes of cancer: a comparative analysis of Hodgkin's disease and testicular cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17363839" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Impact of fatigue on overall quality of life in lung and breast cancer patients selected for high-dose radiotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17532179" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The relationship between cancer-related fatigue and patient satisfaction with quality of life in cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12855263" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Cancer, fatigue and the return of patients to work-a prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11038033" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Cancer-related fatigue: inevitable, unimportant and untreatable? Results of a multi-centre patient survey. Cancer Fatigue Forum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18688057" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Evidence-based recommendations for cancer fatigue, anorexia, depression, and dyspnea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24733803" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Screening, assessment, and management of fatigue in adult survivors of cancer: an American Society of Clinical Oncology clinical practice guideline adaptation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24733803" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Screening, assessment, and management of fatigue in adult survivors of cancer: an American Society of Clinical Oncology clinical practice guideline adaptation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35661856" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Effect of Electronic Symptom Monitoring on Patient-Reported Outcomes Among Patients With Metastatic Cancer: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23737693" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : A pan-Canadian practice guideline and algorithm: screening, assessment, and supportive care of adults with cancer-related fatigue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17441401" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Putting evidence into practice: evidence-based interventions for fatigue during and following cancer and its treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23284036" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Systematic monitoring and treatment of physical symptoms to alleviate fatigue in patients with advanced cancer: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16632079" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Efficacy of darbepoetin alfa in alleviating fatigue and the effect of fatigue on quality of life in anemic patients with lymphoproliferative malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17954713" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20559064" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : American College of Sports Medicine roundtable on exercise guidelines for cancer survivors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14554239" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Cancer-related fatigue: can exercise physiology assist oncologists?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11157015" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Structured exercise improves physical functioning in women with stages I and II breast cancer: results of a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9345021" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Effects of aerobic exercise on the physical performance and incidence of treatment-related complications after high-dose chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15274068" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : A randomized, controlled trial of aerobic exercise for treatment-related fatigue in men receiving radical external beam radiotherapy for localized prostate carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15800330" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Effectiveness of physical activity on cardiorespiratory fitness and health-related quality of life in young and middle-aged cancer patients shortly after chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21640547" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Body composition, physical fitness, functional performance, quality of life, and fatigue benefits of exercise for prostate cancer patients: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35107601" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Effectiveness of exercise training on cancer-related fatigue in colorectal cancer survivors: a systematic review and meta-analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23834462" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : A systematic review and meta-analysis of exercise interventions for colorectal cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32361988" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Physical activity interventions for disease-related physical and mental health during and following treatment in people with non-advanced colorectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32972439" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Exercise and colorectal cancer: a systematic review and meta-analysis of exercise safety, feasibility and effectiveness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19637345" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Impact of a walking intervention on cardiorespiratory fitness, self-reported physical function, and pain in patients undergoing treatment for solid tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12942360" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Effects of endurance training on the physical performance of patients with hematological malignancies during chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10326708" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Effects of physical activity on the fatigue and psychologic status of cancer patients during chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12721239" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Randomized controlled trial of exercise training in postmenopausal breast cancer survivors: cardiopulmonary and quality of life outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19687337" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Randomized controlled trial of the effects of aerobic exercise on physical functioning and quality of life in lymphoma patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12721238" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Resistance exercise in men receiving androgen deprivation therapy for prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19064985" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Randomized controlled trial of resistance or aerobic exercise in men receiving radiation therapy for prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25096607" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Randomized, controlled trial of resistance training in breast cancer patients receiving adjuvant radiotherapy: results on cancer-related fatigue and quality of life.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25484317" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Effects of resistance exercise on fatigue and quality of life in breast cancer patients undergoing adjuvant chemotherapy: A randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23017985" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : The effectiveness of a deep water aquatic exercise program in cancer-related fatigue in breast cancer survivors: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17530428" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Effects of a combined aerobic and resistance exercise program in breast cancer survivors: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19826172" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Effect of a multimodal high intensity exercise intervention in cancer patients undergoing chemotherapy: randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21948693" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Physical exercise for cancer patients with advanced disease: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23017624" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : A home-based exercise program to improve function, fatigue, and sleep quality in patients with Stage IV lung and colorectal cancer: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11323538" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Exercise reduces daily fatigue in women with breast cancer receiving chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34649267" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Home-based Physical Activity to Alleviate Fatigue in Cancer Survivors: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35576506" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Exercise, Diet, and Weight Management During Cancer Treatment: ASCO Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28501804" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Exercise and other non-pharmaceutical interventions for cancer-related fatigue in patients during or after cancer treatment: a systematic review incorporating an indirect-comparisons meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29458789" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Physical activity reduces fatigue in patients with cancer and hematopoietic stem cell transplant recipients: A systematic review and meta-analysis of randomized trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30702150" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Aerobic physical exercise for adult patients with haematological malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32842816" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : The effects of exercise on cancer-related fatigue in breast cancer patients during primary treatment: a meta-analysis and systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33989413" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : People With Hematological Malignancies Treated With Bone Marrow Transplantation Have Improved Function, Quality of Life, and Fatigue Following Exercise Intervention: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32074040" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : The Impact of Exercise during Radiation Therapy for Prostate Cancer on Fatigue and Quality of Life: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32828706" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Effect of Exercise on Physical Function and Psychological Well-being in Older Patients With Colorectal Cancer Receiving Chemotherapy-A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33008682" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Exercise for Individuals With Lung Cancer: A Systematic Review and Meta-Analysis of Adverse Events, Feasibility, and Effectiveness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30955185" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Effects of physical and mind-body exercise on sleep problems during and after breast cancer treatment: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17557948" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Randomized controlled trial of the effects of print materials and step pedometers on physical activity and quality of life in breast cancer survivors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31524827" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Moderators of Exercise Effects on Cancer-related Fatigue: A Meta-analysis of Individual Patient Data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32173483" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Cancer-related fatigue: ESMO Clinical Practice Guidelines for diagnosis and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15022300" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : A randomized clinical trial of energy conservation for patients with cancer-related fatigue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16488348" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Supportive intervention for fatigue in patients undergoing chemotherapy: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17661342" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : A randomized controlled trial to evaluate the effectiveness of a brief, behaviorally oriented intervention for cancer-related fatigue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16135471" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Randomized controlled trial of an educational intervention for managing fatigue in women receiving adjuvant chemotherapy for early-stage breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18981466" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Nonpharmacologic strategies for managing common chemotherapy adverse effects: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19160308" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Psychosocial interventions for reducing fatigue during cancer treatment in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22771125" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Pilot randomized controlled trial of a patient-controlled cognitive-behavioral intervention for the pain, fatigue, and sleep disturbance symptom cluster in cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24419112" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Randomized controlled trial of a cognitive-behavioral therapy plus hypnosis intervention to control fatigue in patients undergoing radiotherapy for breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31912784" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Cognitive behavioral therapy or graded exercise therapy compared with usual care for severe fatigue in patients with advanced cancer during treatment: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17653075" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Cognitive behaviour therapy for fatigued cancer survivors: long-term follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28708236" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Psychosocial interventions for fatigue during cancer treatment with palliative intent.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16462503" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Will improvement in quality of life (QOL) impact fatigue in patients receiving radiation therapy for advanced cancer?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16446335" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Impacting quality of life for patients with advanced cancer with a structured multidisciplinary intervention: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20336645" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Effectiveness of behavioral techniques and physical exercise on psychosocial functioning and health-related quality of life in breast cancer patients and survivors--a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22383268" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Mindfulness-based cognitive therapy reduces chronic cancer-related fatigue: a treatment study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18020836" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Systematic review and meta-analysis of psychological and activity-based interventions for cancer-related fatigue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18729569" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Cancer-related fatigue: a systematic and meta-analytic review of non-pharmacological therapies for cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14752074" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Effect of a cognitive behavioral intervention on reducing symptom severity during chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12394560" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : A pilot study examining energy conservation for cancer treatment-related fatigue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7866973" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Fatigue-reducing strategies used by patients receiving treatment for cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9055119" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Self-care behaviours initiated by chemotherapy patients in response to fatigue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14722591" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Virtual reality as a distraction intervention for women receiving chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14564493" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Support groups for cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10762094" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Group support interventions for women with breast cancer: who benefits from what?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8214179" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Group psychotherapy during radiotherapy: effects on emotional and physical distress.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15718325" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Psychoeducational intervention for patients with cutaneous malignant melanoma: a replication study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3966583" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Psychotherapy during radiotherapy: effects on emotional and physical distress.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12096292" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Pain and fatigue management: results of a nursing randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1502290" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Effects of psychological treatment on cancer patients: a critical review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12065562" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Efficacy and costs of two forms of stress management training for cancer patients undergoing chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1602030" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Relaxation therapy as an adjunct in radiation oncology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14749092" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Mindfulness-based stress reduction in relation to quality of life, mood, symptoms of stress and levels of cortisol, dehydroepiandrosterone sulfate (DHEAS) and melatonin in breast and prostate cancer outpatients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11747061" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : The effectiveness of relaxation training in reducing treatment-related symptoms and improving emotional adjustment in acute non-surgical cancer treatment: a meta-analytical review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10939175" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : The effectiveness of the comprehensive coping strategy program on clinical outcomes in breast cancer autologous bone marrow transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17050873" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Effects of cognitive behavior therapy in severely fatigued disease-free cancer patients compared with patients waiting for cognitive behavior therapy: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16135469" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Outcomes from the Moving Beyond Cancer psychoeducational, randomized, controlled trial with breast cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22412149" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Web-based tailored education program for disease-free cancer survivors with cancer-related fatigue: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14661683" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Group and individual treatment strategies for distress in cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21506018" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Mindfulness based stress reduction in post-treatment breast cancer patients: an examination of symptoms and symptom clusters.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22430268" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Effectiveness of mindfulness-based stress reduction in mood, breast- and endocrine-related quality of life, and well-being in stage 0 to III breast cancer: a randomized, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27189614" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Randomized controlled pilot trial of mindfulness-based stress reduction compared to psychoeducational support for persistently fatigued breast and colorectal cancer survivors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25537522" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Mindfulness meditation for younger breast cancer survivors: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33460741" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : The mindfulness-based stress reduction program for improving sleep quality in cancer survivors: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31927347" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Mindfulness-based stress reduction can alleviate cancer- related fatigue: A meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22180393" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Yoga for persistent fatigue in breast cancer survivors: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23940231" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Multicenter, randomized controlled trial of yoga for sleep quality among cancer survivors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24470004" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Yoga's impact on inflammation, mood, and fatigue in breast cancer survivors: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24590636" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Randomized, controlled trial of yoga in women with breast cancer undergoing radiotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21355946" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Effect of Iyengar yoga practice on fatigue and diurnal salivary cortisol concentration in breast cancer survivors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33026490" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Yoga effectively reduces fatigue and symptoms of depression in patients with different types of cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25739642" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Yoga and meditation for menopausal symptoms in breast cancer survivors-A randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21207071" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Randomized controlled pilot trial of yoga in overweight and obese breast cancer survivors: effects on quality of life and anthropometric measures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19242916" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Restorative yoga for women with breast cancer: findings from a randomized pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20388445" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Yoga improves quality of life and benefit finding in women undergoing radiotherapy for breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30247961" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : A Randomized Study of Yoga for Fatigue and Quality of Life in Women with Breast Cancer Undergoing (Neo) Adjuvant Chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31165647" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Influence of Yoga on Cancer-Related Fatigue and on Mediational Relationships Between Changes in Sleep and Cancer-Related Fatigue: A Nationwide, Multicenter Randomized Controlled Trial of Yoga in Cancer Survivors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31127466" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Yoga has a solid effect on cancer-related fatigue in patients with breast cancer: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23334562" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Acupuncture for the treatment of post-chemotherapy chronic fatigue: a randomized, blinded, sham-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15117996" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Acupuncture for postchemotherapy fatigue: a phase II study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18054724" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : The management of cancer-related fatigue after chemotherapy with acupuncture and acupressure: a randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23109700" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Acupuncture for cancer-related fatigue in patients with breast cancer: a pragmatic randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21703001" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Patient education integrated with acupuncture for relief of cancer-related fatigue randomized controlled feasibility study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25077452" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Electroacupuncture for fatigue, sleep, and psychological distress in breast cancer patients with aromatase inhibitor-related arthralgia: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23196311" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : The effect of acupuncture on post-cancer fatigue and well-being for women recovering from breast cancer: a pilot randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21666275" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Is there a role for acupuncture in the symptom management of patients receiving palliative care for cancer? A pilot study of 20 patients comparing acupuncture with nurse-led supportive care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19476729" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Pilot, randomized, modified, double-blind, placebo-controlled trial of acupuncture for cancer-related fatigue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23436910" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : A randomized, controlled trial of acupuncture self-needling as maintenance therapy for cancer-related fatigue after therapist-delivered acupuncture.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23610109" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Do randomized acupuncture studies in patients with cancer need a sham acupuncture control arm?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29128952" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Effects of acupuncture on cancer-related fatigue: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27467589" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Randomized controlled trial of the Valencia model of waking hypnosis plus CBT for pain, fatigue, and sleep management in patients with cancer and cancer survivors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19450037" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Fatigue during breast cancer radiotherapy: an initial randomized study of cognitive-behavioral therapy plus hypnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25233905" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Hypnosis in breast cancer care: a systematic review of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29929493" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Efficacy of a hypnosis-based intervention to improve well-being during cancer: a comparison between prostate and breast cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19226611" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : A randomized trial of a cognitive-behavioral therapy and hypnosis intervention on positive and negative affect during breast cancer radiotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29222705" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Tai Chi and Qigong for cancer-related symptoms and quality of life: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25124456" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Randomized controlled trial of Qigong/Tai Chi Easy on cancer-related fatigue in breast cancer survivors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26721747" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Tai Chi Exercise for Cancer-Related Fatigue in Patients With Lung Cancer Undergoing Chemotherapy: A Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29122618" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Effects of Tai Chi Exercise on Cancer-Related Fatigue in Patients With Nasopharyngeal Carcinoma Undergoing Chemoradiotherapy: A Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31266043" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Effect of Baduanjin Qigong Exercise on Cancer-Related Fatigue in Patients with Colorectal Cancer Undergoing Chemotherapy: A Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28489508" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Tai Chi Chih Compared With Cognitive Behavioral Therapy for the Treatment of Insomnia in Survivors of Breast Cancer: A Randomized, Partially Blinded, Noninferiority Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29564620" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Ameliorative effects of Tai Chi on cancer-related fatigue: a meta-analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23632236" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : A systematic review of complementary and alternative medicine interventions for the management of cancer-related fatigue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34043051" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : The effect of massage therapy on fatigue after chemotherapy in gastrointestinal cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33481115" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Music interventions can alleviate cancer-related fatigue: a metaanalysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29633652" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : Music Therapy Reduces Radiotherapy-Induced Fatigue in Patients With Breast or Gynecological Cancer: A Randomized Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35689676" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : The effect of music therapy interventions on fatigue in patients with hematological cancers: a systematic review and meta-analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28436999" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : Clinical practice guidelines on the evidence-based use of integrative therapies during and after breast cancer treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29889605" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : Integrative Therapies During and After Breast Cancer Treatment: ASCO Endorsement of the SIO Clinical Practice Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16648508" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : Patient-controlled methylphenidate for cancer fatigue: a double-blind, randomized, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16648508" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : Patient-controlled methylphenidate for cancer fatigue: a double-blind, randomized, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20614448" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : Drug therapy for the management of cancer-related fatigue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19896571" id="rid148" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>149 : Efficacy of dexmethylphenidate for the treatment of fatigue after cancer chemotherapy: a randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18790598" id="rid149" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>150 : A randomized, double-blind, placebo-controlled trial assessing the impact of dexamphetamine on fatigue in patients with advanced cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17972110" id="rid150" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>151 : A randomised, placebo-controlled, double-blind trial of the effects of d-methylphenidate on fatigue and cognitive dysfunction in women undergoing adjuvant chemotherapy for breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17869448" id="rid151" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>152 : A phase III, double-blind, placebo-controlled prospective randomized clinical trial of d-threo-methylphenidate HCl in brain tumor patients receiving radiation therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20625123" id="rid152" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>153 : Phase III, randomized, double-blind, placebo-controlled study of long-acting methylphenidate for cancer-related fatigue: North Central Cancer Treatment Group NCCTG-N05C7 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23690414" id="rid153" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>154 : Methylphenidate and/or a nursing telephone intervention for fatigue in patients with advanced cancer: a randomized, placebo-controlled, phase II trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22208450" id="rid154" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>155 : Effects of methylphenidate on fatigue and depression: a randomized, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24445757" id="rid155" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>156 : A randomized, double-blind, 2-period, placebo-controlled crossover trial of a sustained-release methylphenidate in the treatment of fatigue in cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23690419" id="rid156" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>157 : Methylphenidate in the management of cancer-related fatigue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7539701" id="rid157" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>158 : A randomized, crossover evaluation of methylphenidate in cancer patients receiving strong narcotics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19270033" id="rid158" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>159 : Modafinil for the treatment of fatigue in lung cancer: a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19416039" id="rid159" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>160 : A pilot study evaluating the safety and efficacy of modafinal for cancer-related fatigue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20564068" id="rid160" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>161 : A phase 3 randomized, placebo-controlled, double-blind, clinical trial of the effect of modafinil on cancer-related fatigue among 631 patients receiving chemotherapy: a University of Rochester Cancer Center Community Clinical Oncology Program Research base study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24778393" id="rid161" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>162 : Modafinil for the treatment of fatigue in lung cancer: results of a placebo-controlled, double-blind, randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20457506" id="rid162" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>163 : Associations among hypogonadism, C-reactive protein, symptom burden, and survival in male cancer patients with cachexia: a preliminary report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23102563" id="rid163" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>164 : The effect of severe androgen deficiency on physical function in male patients with cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23653013" id="rid164" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>165 : Testosterone replacement for fatigue in hypogonadal ambulatory males with advanced cancer: a preliminary double-blind placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33512910" id="rid165" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>166 : Testosterone for Managing Treatment-related Fatigue in Patients With Metastatic Renal Cell Carcinoma: A Phase 2 Randomized Study FARETES.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14673053" id="rid166" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>167 : Differential effects of paroxetine on fatigue and depression: a randomized, double-blind trial from the University of Rochester Cancer Center Community Clinical Oncology Program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17548243" id="rid167" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>168 : Effect of sertraline on symptoms and survival in patients with advanced cancer, but without major depression: a placebo-controlled double-blind randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22858235" id="rid168" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>169 : Impact of paroxetine on sleep problems in 426 cancer patients receiving chemotherapy: a trial from the University of Rochester Cancer Center Community Clinical Oncology Program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2410117" id="rid169" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>170 : Action of oral methylprednisolone in terminal cancer patients: a prospective randomized double-blind study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23897970" id="rid170" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>171 : Reduction of cancer-related fatigue with dexamethasone: a double-blind, randomized, placebo-controlled trial in patients with advanced cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36688471" id="rid171" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>172 : Corticosteroids for the management of cancer-related fatigue in adults with advanced cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27233138" id="rid172" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>173 : Predictors of Responses to Corticosteroids for Cancer-Related Fatigue in Advanced Cancer Patients: A Multicenter, Prospective, Observational Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19415341" id="rid173" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>174 : Pilot study of Panax quinquefolius (American ginseng) to improve cancer-related fatigue: a randomized, double-blind, dose-finding evaluation: NCCTG trial N03CA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23853057" id="rid174" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>175 : Wisconsin Ginseng (Panax quinquefolius) to improve cancer-related fatigue: a randomized, double-blind trial, N07C2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32172198" id="rid175" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>176 : Korean red ginseng for cancer-related fatigue in colorectal cancer patients with chemotherapy: A randomised phase III trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22670731" id="rid176" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>177 : Herb-drug interactions: an overview of systematic reviews.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22292789" id="rid177" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>178 : Herb-drug interactions and mechanistic and clinical considerations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20332334" id="rid178" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>179 : Imatinib and Panax ginseng: a potential interaction resulting in liver toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19719333" id="rid179" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>180 : Interactions between herbal medicines and prescribed drugs: an updated systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23394826" id="rid180" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>181 : Relevance of in vitro and clinical data for predicting CYP3A4-mediated herb-drug interactions in cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21612429" id="rid181" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>182 : Guarana (Paullinia cupana) improves fatigue in breast cancer patients undergoing systemic chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19388866" id="rid182" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>183 : Effectiveness of guaraná(Paullinia cupana) for postradiation fatigue and depression: results of a pilot double-blind randomized study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34146166" id="rid183" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>184 : The use of guarana (Paullinia cupana) as a dietary supplement for fatigue in cancer patients: a systematic review with a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17762445" id="rid184" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>185 : Multivitamins do not improve radiation therapy-related fatigue: results of a double-blind randomized crossover trial.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
